AMINO LIPID COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Abstract

The present invention discloses an amino lipid compound, a preparation method and use of the same. The present invention also provides lipid particles comprising the amino lipid compound, and use thereof for delivering bioactive agents into cells. The present invention also provides a use of lipid particles comprising the amino lipid as a medicament.

Claims

1. An amino lipid compound, wherein the amino lipid compound is a compound represented by Formula I: ##STR00116## wherein: R.sup.1 and R.sup.2 are the same or different from each other, and are each independently selected from the group consisting of C.sub.6-C.sub.24 alkyl, C.sub.6-C.sub.24 alkenyl, C.sub.6-C.sub.24 alkynyl and C.sub.4-C.sub.24 acyl, wherein the C.sub.6-C.sub.24 alkyl, the C.sub.6-C.sub.24 alkenyl, the C.sub.6-C.sub.24 alkynyl and the C.sub.4-C.sub.24 acyl are optionally substituted with C.sub.1-C.sub.6 hydrocarbyl; X.sup.1 is selected from the group consisting of C, O, S, S═O, S(═O).sub.2 and S—S; X.sup.2 and X.sup.3 are the same or different from each other, and are each independently selected from the group consisting of C, N, O, S, S═O, S(═O).sub.2 and S—S; when X.sup.1 is C, m=2, and two R.sup.6 are the same or different from each other; when X.sup.1 is O, S, S═O, S(═O).sub.2 or S—S, m=0; when X.sup.2 is C, n=2, and two R.sup.7 are the same or different from each other; when X.sup.2 is N, n=1; when X.sup.2 is O, S, S═O, S(═O).sub.2 or S—S, n=0; when X.sup.3 is C, p=2, and two R.sup.8 are the same or different from each other; when X.sup.3 is N, p=1; when X.sup.3 is O, S, S═O, S(═O).sub.2 or S—S, p=0; R.sup.3 and R.sup.4 are the same or different from each other, and are each independently selected from C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl and C.sub.2-C.sub.12 alkynyl, wherein the C.sub.1-C.sub.12 alkyl, the C.sub.2-C.sub.12 alkenyl and the C.sub.2-C.sub.12 alkynyl are optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, or R.sup.3 and R.sup.4 bind to each other to form an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from nitrogen, sulfur, and oxygen; R.sup.5 is absent, or R.sup.5 is hydrogen or C.sub.1-C.sub.12 alkyl to provide a quaternary amine; R.sup.6, R.sup.7, R.sup.8 are hydrogen or C.sub.1-C.sub.12 alkyl; L is C.sub.1-C.sub.12 alkylene, C.sub.2-C.sub.12 alkenylene or C.sub.2-C.sub.12 alkynylene, wherein the C.sub.1-C.sub.12 alkylene, the C.sub.2-C.sub.12 alkenylene and the C.sub.2-C.sub.12 alkynylene are optionally substituted with one or more substituents selected from the group consisting of hydrocarbyl, carboxyl, acyl and alkoxy, or L is an optionally substituted 4-10 membered heterocycle containing heteroatoms selected from nitrogen, sulfur, and oxygen.

2. The amino lipid compound according to claim 1, wherein: X.sup.1 is C, R.sup.6 is H, and m=2; or X.sup.1 is O, S, S═O, S(═O).sub.2 or S—S, and m=0; and/or X.sup.2 is C, R.sup.7 is H, and n=2; or X.sup.2 is N, R.sup.7 is H, and n=1; or X.sup.2 is O, S, S═O, S(═O).sub.2 or S—S, n=0; and/or X.sup.3 is C, R.sup.8 is H, and p=2; or X.sup.3 is N, R.sup.8 is H, and p=1; or X.sup.3 is O, S, S═O, S(═O).sub.2 or S—S, and p=0.

3. The amino lipid compound according to claim 1, wherein: X.sup.2 is N or S; when X.sup.1 is S, m=0; wherein when X.sup.2 is N, n=1; when X.sup.2 is S, n=0; and/or X.sup.3 is N and p=1, or X.sup.3 is O and p=0; and/or R.sup.5 is absent; and/or L is C.sub.1-C.sub.12 alkylene, wherein the C.sub.1-C.sub.12 alkylene is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl.

4. The amino lipid compound according to claim 3, wherein: when n=1, R.sup.7 is hydrogen; and/or R.sup.8 is hydrogen.

5. The amino lipid compound according to claim 1, wherein: R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.24 alkyl or C.sub.6-C.sub.24 alkenyl; X.sup.1 is S, and m=O; X.sup.2 is N, R.sup.7 is H, and n=1; or X.sup.2 is S, and n=0; X.sup.3 is N, R.sup.8 is H, and p=1; R.sup.3 and R.sup.4 are the same or different from each other, and are each independently C.sub.1-C.sub.12 alkyl wherein the C.sub.1-C.sub.12 alkyl is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, or R.sup.3 and R.sup.4 bind to each other to form an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from nitrogen, sulfur, and oxygen; and R.sup.5 is absent.

6. The amino lipid compound according to claim 1, wherein: L is C.sub.1-C.sub.4 alkylene, wherein the C.sub.1-C.sub.4 alkylene is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl.

7. The amino lipid compound according to claim 1, wherein: R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.18 alkyl or C.sub.6-C.sub.18 alkenyl.

8. The amino lipid compound according to claim 1, wherein: m=0, n=0 or 1, and ##STR00117## is one selected from S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, S19, and S20, and ##STR00118##  is one selected from S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, S19, S20, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18 and .sup.2N.sub.12: S6: CH.sub.3(CH.sub.2).sub.5S—; S7: CH.sub.3(CH.sub.2).sub.6S—; S8: CH.sub.3(CH.sub.2).sub.7S—; S9: CH.sub.3(CH.sub.2).sub.5S—; S10: CH.sub.3(CH.sub.2).sub.9S—; S11: CH.sub.3(CH.sub.2).sub.10S—; S12: CH.sub.3(CH.sub.2).sub.11S—; S14: CH.sub.3(CH.sub.2).sub.13S—; S15: CH.sub.3(CH.sub.2).sub.14S—; S16: CH.sub.3(CH.sub.2).sub.15S—; S18: CH.sub.3(CH.sub.2).sub.17S—; ##STR00119## N6: CH.sub.3(CH.sub.2).sub.5NH—; N7: CH.sub.3(CH.sub.2).sub.6NH—; N8: CH.sub.3(CH.sub.2).sub.7NH—; N9: CH.sub.3(CH.sub.2).sub.8NH—; N11: CH.sub.3(CH.sub.2).sub.10NH—; N12: CH.sub.3(CH.sub.2).sub.11NH—; N13: CH.sub.3(CH.sub.2).sub.12NH—; N15: CH.sub.3(CH.sub.2).sub.14NH—; N16: CH.sub.3(CH.sub.2).sub.15NH—; N18: CH.sub.3(CH.sub.2).sub.17NH—; .sup.2N.sub.12: (CH.sub.3(CH.sub.2).sub.11).sub.2N—.

9. The amino lipid compound according to claim 1, wherein: p=1, and ##STR00120## is one selected from D1, D2, D3, D4, D5, D6, D7, D8, D9 and D10: ##STR00121##

10. The amino lipid compound according to claim 1, wherein: X.sup.3 is O; p is 0; R.sup.5 is absent; and ##STR00122## is one selected from O1, O2, O3, O4, O5, O6, O7, O8, O9 and O10: ##STR00123##

11. A method for preparing the amino lipid compound according to claim 1, the method comprising the steps of: (1) performing a first reaction between cyanuric chloride and a compound represented by R.sup.1(R.sup.6).sub.m—X.sup.1H at a temperature of −40° C. to 30° C. in the presence of a base as an acid-binding agent to obtain a first intermediate of Formula I-1; ##STR00124## (2) with or without separating the first intermediate, performing a second reaction between the first intermediate and a compound represented by R.sup.2(R.sup.7).sub.n—X.sup.2H at room temperature or under a heating condition in the presence of a base as an acid-binding agent to obtain a second intermediate of Formula I-2; ##STR00125## (3) with or without separating the second intermediate, performing a third reaction between the second intermediate and a diamine represented by HX.sup.3(R.sup.8).sub.p-L-NR.sup.3R.sup.4R.sup.5 under a heating condition, to obtain the amino lipid compound of Formula I; wherein the definitions of X.sup.1, X.sup.2, X.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, m, n and p are the same as the definitions thereof in claim 1.

12. (canceled)

13. Lipid particles comprising the amino lipid compound according to claim 1.

14. The lipid particles according to claim 13, wherein the lipid particles further contain one or more of a helper lipid, a sterol and a bioactive agent.

14-20. (canceled)

21. The lipid particles according to claim 14, wherein: the lipid particles further contain polyethylene glycol (PEG)-lipid; and/or the molar ratio of the amino lipid compound to the helper lipid in the lipid particles is about (2 to 10):1; and/or the molar ratio of the amino lipid compound to the sterol in the lipid particles is about (0.5 to 1.5):1; and/or the helper lipid is a non-cationic lipid; and/or the sterol is one or more selected from the group consisting of cholesterol, sitosterol, stigmasterol and ergosterol; and/or the bioactive agent is one or more of a nucleic acid, an antitumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, an antigen or a fragment thereof, a peptide, a protein, an antibody, a vaccine and a small molecule.

22. The lipid particles according to claim 21, wherein: the molar ratio of the amino lipid compound to the helper lipid in the lipid particles is preferably about (3 to 8):1; and/or the molar ratio of the amino lipid compound to the sterol in the lipid particles is about (1 to 1.4):1; and/or the molar ratio of the amino lipid compound to the PEG-lipid in the lipid particles is about (9 to 42):1; and/or the helper lipid is a non-cationic phospholipid; and/or the sterol is cholesterol; and/or the PEG-lipid is one or more selected from the group consisting of PEG1000-DMG, PEG5000-DMG, PEG2000-DMG and PEG2000-DSPE; and/or the nucleic acid is RNA, messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small interfering RNA (siRNA) and small nuclear RNA (snRNA).

23. Use of the lipid particles according to claim 13 in the preparation of a medicament for nucleic acid transfer, gene therapy, gene vaccination, antisense therapy or a therapy by RNA interference

24. The use according to claim 23, wherein the lipid particles are used as vectors for encapsulating a bioactive agent; and/or the gene therapy is useful for the treatment of a cancer and a genetic disease; and/or the gene vaccination is useful for the treatment of a cancer, allergy, toxicity and pathogen infection; and/or the nucleic acid is RNA, messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small interfering RNA (siRNA) and small nuclear RNA (snRNA).

25. The use according to claim 24, wherein: the cancer is one or more of lung cancer, gastric cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphatic cancer, hematologic cancer or prostate cancer; and/or the genetic disease is one or more of hemophilia, thalassemia and Gaucher disease; and/or the pathogen is one or more of viruses, bacteria or fungi.

26. New claim: The amino lipid compound according to claim 3, wherein L is (CH.sub.2).sub.q, wherein q is an integer of from 1 to 12.

27. The lipid particles according to claim 13, wherein the lipid particles are lipid nanoparticles, liposomes, multilayered vesicles or micelles.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] FIG. 1 shows the humoral antibody titer produced by subcutaneous administration of ovalbumin mRNA (OVA mRNA) by representative amino lipid compounds.

[0023] FIG. 2 shows the microscopic images of HEK293 cells after treatment with a reference reagent (Lipofectamine2000) and S8N12D6 according to Example 4, wherein FIG. 2(a) shows the bright field image of HEK293 cells after treatment with the reference reagent (Lipofectamine2000); FIG. 2(b) shows the bright field image of HEK293 cells after treatment with S8N12D6 according to Example 4; FIG. 2(c) shows the Hoechst staining image of HEK293 nuclei after treatment with the reference reagent (Lipofectamine2000); FIG. 2(d) shows the Hoechst staining image of HEK293 nuclei after treatment with S8N12D6 according to Example 4; FIG. 2(e) shows the GFP image of HEK293 cells after treatment with the reference reagent (Lipofectamine2000); and FIG. 2(f) shows the GFP image of HEK293 cells after treatment with S8N12D6 according to Example 4.

DETAILED DESCRIPTION OF THE INVENTION

[0024] The present invention will be further described in detail hereinafter.

[0025] As used herein, the term “optionally substituted” means that one or more hydrogen atoms linked to an atom or group are independently unsubstituted or substituted with one or more, e.g., one, two, three or four substituents which are independently selected from: deuterium (D), halogen, —OH, mercapto, cyano, —CD.sub.3, C.sub.1-C.sub.6 alkyl (preferably C.sub.1-C.sub.3 alkyl), C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, cycloalkyl (preferably C.sub.3-C.sub.8 cycloalkyl), aryl, heterocyclyl (preferably 3-8 membered heterocyclyl), heteroaryl, aryl-C.sub.1-C.sub.6 alkyl-, heteroaryl-C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 haloalkyl, —OC.sub.1—C.sub.6 alkyl (preferably —OC.sub.1—C.sub.3 alkyl), —OC.sub.2—C.sub.6 alkenyl, OC.sub.1—C.sub.6 alkylphenyl, C.sub.1-C.sub.6 alkyl-OH (preferably C.sub.1-C.sub.4 alkyl-OH), C.sub.1-C.sub.6 alkyl-SH, C.sub.1-C.sub.6 alkyl-O—C.sub.1-C.sub.6 alkyl, OC.sub.1—C.sub.6 haloalkyl, NH.sub.2, C.sub.1-C.sub.6 alkyl-NH.sub.2 (preferably C.sub.1-C.sub.3 alkyl-NH.sub.2), —N(C.sub.1-C.sub.6 alkyl).sub.2 (preferably —N(C.sub.1-C.sub.3 alkyl).sub.2), —NH(C.sub.1-C.sub.6 alkyl) (preferably —NH(C.sub.1-C.sub.3 alkyl)), —N(C.sub.1-C.sub.6 alkyl)(C.sub.1-C.sub.6 alkylphenyl), —NH(C.sub.1-C.sub.6 alkylphenyl), nitro, —C(O)—OH, —C(O)OC.sub.1—C.sub.6 alkyl (preferably —C(O)OC.sub.1—C.sub.3 alkyl), —CONRiRii (wherein Ri and Rii are H, D and C.sub.1-C.sub.6 alkyl, preferably C.sub.1-C.sub.3 alkyl), —NHC(O)(C.sub.1-C.sub.6 alkyl), —NHC(O)(phenyl), —N(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl), —N(C.sub.1-C.sub.6 alkyl)C(O)(phenyl), —C(O)C.sub.1-C.sub.6 alkyl, —C(O)heteroaryl (preferably —C(O)-5-7 membered heteroaryl), —C(O)C.sub.1-C.sub.6 alkylphenyl, —C(O)C.sub.1-C.sub.6 haloalkyl, —OC(O)C.sub.1-C.sub.6 alkyl (preferably —OC(O)C.sub.1-C.sub.3 alkyl), —S(O).sub.2—C.sub.1-C.sub.6 alkyl, —S(O)—C.sub.1-C.sub.6 alkyl, —S(O).sub.2-phenyl, —S(O).sub.2—C.sub.1-C.sub.6 haloalkyl, —S(O).sub.2NH.sub.2, —S(O).sub.2NH(C.sub.1-C.sub.6 alkyl), —S(O).sub.2NH(phenyl), —NHS(O).sub.2(C.sub.1-C.sub.6 alkyl), —NHS(O).sub.2(phenyl) and —NHS(O).sub.2(C.sub.1-C.sub.6 haloalkyl), wherein each of the alkyl, cycloalkyl, phenyl, aryl, heterocyclyl and heteroaryl groups is optionally further substituted with one or more substituents selected from the group consisting of halogen, —OH, —NH.sub.2, cycloalkyl, 3-8 membered heterocyclyl, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 haloalkyl-, —OC.sub.1—C.sub.4 alkyl, —C.sub.1-C.sub.4 alkyl-OH, —C.sub.1-C.sub.4 alkyl-O—C.sub.1-C.sub.4 alkyl, —OC.sub.1—C.sub.4 haloalkyl, cyano, nitro, —C(O)—OH, —C(O)OC.sub.1—C.sub.6 alkyl, —CON(C.sub.1-C.sub.6 alkyl).sub.2, —CONH(C.sub.1-C.sub.6 alkyl), —CONH.sub.2, —NHC(O)(C.sub.1-C.sub.6 alkyl), —NH(C.sub.1-C.sub.6 alkyl)C(O)(C.sub.1-C.sub.6 alkyl), —SO.sub.2(C.sub.1-C.sub.6 alkyl), —SO.sub.2(phenyl), —SO.sub.2(C.sub.1-C.sub.6 haloalkyl), —SO.sub.2NH.sub.2, —SO.sub.2NH(C.sub.1-C.sub.6 alkyl), —SO.sub.2NH(phenyl), —NHSO.sub.2(C.sub.1-C.sub.6 alkyl), —NHSO.sub.2(phenyl) and —NHSO.sub.2(C.sub.1-C.sub.6 haloalkyl). When an atom or group is substituted with multiple substituents, said multiple substituents may be the same or different.

[0026] As used herein, the term “hydrocarbyl” means the remaining group of an aliphatic hydrocarbon after losing one hydrogen atom, including linear or branched, saturated or unsaturated hydrocarbyl. The hydrocarbyl includes alkyl, alkenyl and alkynyl; preferably, the hydrocarbyl is C.sub.1-C.sub.10 hydrocarbyl, C.sub.1-C.sub.6 hydrocarbyl, or C.sub.1-C.sub.3 hydrocarbyl.

[0027] As used herein, the term “alkyl” refers to C.sub.1-C.sub.24 alkyl, C.sub.1-C.sub.20 alkyl, C.sub.1-C.sub.18 alkyl, C.sub.1-C.sub.12 alkyl, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.24 alkyl, C.sub.3-C.sub.20 alkyl, C.sub.3-C.sub.18 alkyl, C.sub.3-C.sub.12 alkyl, C.sub.3-C.sub.6 alkyl, C.sub.6-C.sub.24 alkyl, C.sub.6-C.sub.20 alkyl, C.sub.6-C.sub.18 alkyl or C.sub.6-C.sub.12 alkyl.

[0028] As used herein, the term “alkenyl” refers to C.sub.2-C.sub.24 alkenyl, C.sub.2-C.sub.20 alkenyl, C.sub.2-C.sub.18 alkenyl, C.sub.2-C.sub.12 alkenyl, C.sub.2-C.sub.6 alkenyl, C.sub.3-C.sub.20 alkenyl, C.sub.3-C.sub.18 alkenyl, C.sub.3-C.sub.12 alkenyl, C.sub.3-C.sub.6 alkenyl, C.sub.6-C.sub.24 alkenyl, C.sub.6-C.sub.20 alkenyl, C.sub.6-C.sub.18 alkenyl or C.sub.6-C.sub.12 alkenyl. Alkenyl may contain one or more (for example, 2, 3 or 4) C═C double bonds.

[0029] As used herein, the term “alkynyl” refers to C.sub.2-C.sub.24 alkynyl, C.sub.2-C.sub.20 alkynyl, C.sub.2-C.sub.18 alkynyl, C.sub.2-C.sub.12 alkynyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.20 alkynyl, C.sub.3-C.sub.18 alkynyl, C.sub.3-C.sub.12 alkynyl, C.sub.3-C.sub.6 alkynyl, C.sub.6-C.sub.24 alkynyl, C.sub.6-C.sub.20 alkynyl, C.sub.6-C.sub.18 alkynyl or C.sub.6-C.sub.12 alkynyl.

[0030] As used herein, the term “acyl” means hydrocarbyl-carbonyl. Preferably, the acyl is C.sub.4-C.sub.24 acyl, C.sub.6-C.sub.18 acyl, C.sub.6-C.sub.12 acyl, C.sub.6-C.sub.10 acyl, C.sub.4-C.sub.6 acyl.

[0031] As used herein, the term “alkoxy” means alkyl-oxy. Preferably, the alkoxy is C.sub.1-C.sub.10 alkoxy; more preferably, the alkoxy is C.sub.1-C.sub.6 alkoxy; and most preferably, the alkoxy is C.sub.1-C.sub.3 alkoxy.

[0032] As used herein, the term “heterocycle” means a saturated or unsaturated cyclic group containing heteroatoms selected from N, O and S. Preferably, the heterocycle is an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from N, O and S, or an optionally substituted 4-6 membered saturated heterocycle containing 1, 2 or 3 heteroatoms selected from N, O and S. Examples of heterocycles include, but are not limited to, azetidine, oxetanyl, tetrahydrofuran, pyrrolidine, imidazolidine, pyrazolidine, tetrahydropyran, piperidine, morpholine, thiomorpholine, piperazine, preferably pyrrolidine, piperidine, piperazine and morpholine. The heterocycle may be optionally substituted with one or more substituents, and the types of the substituents are as defined for “optionally substituted” above to which reference is made.

[0033] In one aspect, the present invention provides an amino lipid compound which is a compound represented by the following Formula I:

##STR00002##

[0034] wherein:

[0035] R.sup.1 and R.sup.2 are the same or different from each other, and are each independently selected from the group consisting of C.sub.6-C.sub.24 alkyl, C.sub.6-C.sub.24 alkenyl, C.sub.6-C.sub.24 alkynyl and C.sub.4-C.sub.24 acyl, wherein the C.sub.6-C.sub.24 alkyl, the C.sub.6-C.sub.24 alkenyl, the C.sub.6-C.sub.24 alkynyl and the C.sub.4-C.sub.24 acyl are optionally substituted with C.sub.1-C.sub.6hydrocarbyl;

[0036] preferably, R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.18 alkyl or C.sub.6-C.sub.18 alkenyl.

[0037] X.sup.1, X.sup.2 and X.sup.3 are the same or different from one another, and are each independently selected from the group consisting of C, N, O, S, S═O, S(═O).sub.2 and S—S;

[0038] when X.sup.1 is C, m=2, and two R.sup.6 are the same or different from each other; when X.sup.1 is N, m=1; when X.sup.1 is O, S, S═O, S(═O).sub.2 or S—S, m=0;

[0039] when X.sup.2 is C, n=2, and two R.sup.7 are the same or different from each other; when X.sup.2 is N, n=1; when X.sup.2 is O, S, S═O, S(═O).sub.2 or S—S, n=0;

[0040] when X.sup.3 is C, p=2, and two R.sup.8 are the same or different from each other; when X.sup.3 is N, p=1; when X.sup.3 is O, S, S═O, S(═O).sub.2 or S—S, p=0;

[0041] R.sup.3 and R.sup.4 are the same or different from each other, and are each independently selected from the group consisting of C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl and C.sub.2-C.sub.12 alkynyl, wherein the C.sub.1-C.sub.12 alkyl, the C.sub.2-C.sub.12 alkenyl and the C.sub.2-C.sub.12 alkynyl are optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, or R.sup.3 and R.sup.4 bind to each other to form an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from nitrogen, sulfur, and oxygen;

[0042] R.sup.5 is absent, or R.sup.5 is hydrogen or C.sub.1-C.sub.12 alkyl to provide a quaternary amine;

[0043] R.sup.6, R.sup.7, R.sup.8 are hydrogen or C.sub.1-C.sub.12 alkyl;

[0044] L is C.sub.1-C.sub.12 alkylene, C.sub.2-C.sub.12 alkenylene or C.sub.2-C.sub.12 alkynylene, wherein the C.sub.1-C.sub.12 alkylene, the C.sub.2-C.sub.12 alkenylene and the C.sub.2-C.sub.12 alkenylene are optionally substituted with one or more substituents selected from the group consisting of hydrocarbyl, carboxyl, acyl and alkoxy, or L is an optionally substituted 4-10 membered heterocycle containing heteroatoms selected from nitrogen, sulfur, and oxygen.

[0045] Preferably, L is C.sub.1-C.sub.8 alkylene, C.sub.2-C.sub.6 alkylene, C.sub.2-C.sub.4 alkylene or C.sub.3-C.sub.4 alkylene, wherein the C.sub.1-C.sub.8 alkylene, the C.sub.2-C.sub.6 alkylene, the C.sub.2-C.sub.4 alkylene or the C.sub.3-C.sub.4 alkylene is optionally substituted with C.sub.1-C.sub.6hydrocarbyl.

[0046] In some embodiments, the present invention provides the amino lipid compound of Formula I, wherein X.sup.1 is C, R.sup.6 is H, and m=2; or X.sup.1 is N, R.sup.6 is H and m=1; or X.sup.1 is O, S, S═O, S(═O).sub.2 or S—S, and m=0; alternatively or further, X.sup.2 is C, R.sup.7 is H, and n=2; or X.sup.2 is N, R.sup.7 is H, and n=1; or X.sup.2 is O, S, S═O, S(═O).sub.2 or S—S, n=0; alternatively or further, X.sup.3 is C, R.sup.8 is H, and p=2; or X.sup.3 is N, R.sup.8 is H, and p=1; or X.sup.3 is O, S, S═O, S(═O).sub.2 or S—S, and p=0.

[0047] In some other embodiments, the present invention provides the amino lipid compound of Formula I, wherein X.sup.1 and X.sup.2 are the same or different from each other, and are each independently N or S; when X.sup.1 is N, m=1; when X.sup.1 is S, m=0; when X.sup.2 is N, n=1; when X.sup.2 is S, n=0; alternatively or further, X.sup.3 is N and p=1, or X.sup.3 is O and p=0; alternatively or further, R.sup.5 is absent; alternatively or further, L is C.sub.1-C.sub.12 alkylene which is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, for example, L is (CH.sub.2).sub.q, wherein q is an integer of from 1 to 12, for example, an integer of from 1 to 8 or from 1 to 6. In some of such embodiments, when m=1, R.sup.6 is hydrogen; alternatively or further, when n=1, R.sup.7 is hydrogen; alternatively or further, R.sup.8 is hydrogen. In other such embodiments, the present invention provides the amino lipid compound of Formula I, wherein: R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.24 alkyl or C.sub.6-C.sub.24 alkenyl (for example, C.sub.12-C.sub.18 alkenyl); X.sup.1 is N, R.sup.6 is H, and m=1; or X.sup.1 is S, and m=0; X.sup.2 is N, R.sup.7 is H, and n=1; or X.sup.2 is S, and n=0; X.sup.3 is N, R.sup.8 is H, and p=1; R.sup.3 and R.sup.4 are the same or different from each other, and are each independently C.sub.1-C.sub.12 alkyl, wherein the C.sub.1-C.sub.12 alkyl is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, or R.sup.3 and R.sup.4 bind to each other to form an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from nitrogen, sulfur, and oxygen; and R.sup.5 is absent.

[0048] In some embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein L is C.sub.1-C.sub.4 alkylene, wherein the C.sub.1-C.sub.4 alkylene is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl. For example, L is C.sub.2-C.sub.4 alkylene, such as (CH.sub.2).sub.q, wherein q is 1, 2, 3 or 4.

[0049] In some embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.18 alkyl or C.sub.6-C.sub.18 alkenyl. In some embodiments, R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.18 alkyl. In some embodiments, one of R.sup.1 and R.sup.2 is C.sub.6-C.sub.18 alkyl and the other is C.sub.6-C.sub.18 alkenyl.

[0050] In some embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein:

[0051] m=0 or 1, n=0 or 1, and

##STR00003##

are the same or different from each other, and are each independently one selected from S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, S19, S20, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18 and .sup.2N.sub.12: [0052] S6: CH.sub.3(CH.sub.2).sub.5S—; S7: CH.sub.3(CH.sub.2).sub.6S—; S8: CH.sub.3(CH.sub.2).sub.7S—; [0053] S9: CH.sub.3(CH.sub.2).sub.5S—; S10: CH.sub.3(CH.sub.2).sub.9S—; S11: CH.sub.3(CH.sub.2).sub.10S—; [0054] S12: CH.sub.3(CH.sub.2).sub.11S—; S14: CH.sub.3(CH.sub.2).sub.13S—; S15: CH.sub.3(CH.sub.2).sub.14S—; [0055] S16: CH.sub.3(CH.sub.2).sub.17S—; S15: CH.sub.3(CH.sub.2).sub.17S—; [0056] S19:

##STR00004## [0057] N6: CH.sub.3(CH.sub.2).sub.5NH—; N7: CH.sub.3(CH.sub.2).sub.6NH—; N8: CH.sub.3(CH.sub.2).sub.7NH—; [0058] N9: CH.sub.3(CH.sub.2).sub.8NH—; N11: CH.sub.3(CH.sub.2).sub.10NH—; N12: CH.sub.3(CH.sub.2).sub.11NH—; [0059] N13: CH.sub.3(CH.sub.2).sub.12NH—; N15: CH.sub.3(CH.sub.2).sub.14NH—; N16: CH.sub.3(CH.sub.2).sub.15NH—; [0060] N18: CH.sub.3(CH.sub.2).sub.17NH—; .sup.2N.sub.12: (CH.sub.3(CH.sub.2).sub.11).sub.2N—.

[0061] In some embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein:

[0062] p=1, and

##STR00005##

is one selected from D1, D2, D3, D4, D5, D6, D7, D8, D9 and D10 below:

##STR00006##

[0063] In some embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein: [0064] X.sup.3 is O; [0065] p is 0; [0066] R.sup.5 is absent; and

##STR00007##

is one selected from O1, O2, O3, O4, O5, O6, O7, O8, O9 and O10 below:

##STR00008##

[0067] In some other embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein the amino lipid compound is a compound represented by the following Formula I′:

##STR00009##

[0068] wherein:

[0069] X.sup.1′ and X.sup.2′ are the same or different from each other, and are each independently NH, O or S, preferably NH or S;

[0070] the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and q are the same as the definitions thereof in the above description of the amino lipid compound of Formula I.

[0071] In some other embodiments, the present invention provides the amino lipid compound of Formula I described above, wherein the amino lipid compound is a compound represented by the following Formula I″:

##STR00010##

[0072] wherein:

[0073] the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and q are the same as the definitions thereof in the above description of the amino lipid compound of Formula I.

[0074] In another aspect, the present invention provides a method for preparing the amino lipid compound of Formula I described above, comprising the steps of:

[0075] (1) performing a first reaction between cyanuric chloride and a compound represented by R.sup.1(R.sup.6).sub.m—X.sup.1H at a temperature of −40° C. to 30° C. in the presence of a base as an acid-binding agent to obtain a first intermediate of Formula I-1;

##STR00011##

[0076] (2) with or (preferably) without separating the first intermediate, performing a second reaction between the first intermediate and a compound represented by R.sup.2(R.sup.7).sub.n—X.sup.2H at room temperature or c in the presence of a base as an acid-binding agent to obtain a second intermediate of Formula I-2;

##STR00012##

[0077] (3) with or (preferably) without separating the second intermediate, performing a third reaction between the second intermediate and a diamine represented by HX.sup.3(R.sup.8).sub.p-L-NR.sup.3R.sup.4R.sup.5 under heating condition to obtain the amino lipid compound of Formula I;

[0078] wherein the definitions of X.sup.1, X.sup.2, X.sup.3, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, L, m, n and p are the same as the definitions thereof in the above description of the amino lipid compound of Formula I.

[0079] For example, in some embodiments, X.sup.1 and X.sup.2 are the same or different from each other, and are each independently N or S. When X.sup.1 is N, m=1; when X.sup.1 is S, m=0. When X.sup.2 is N, n=1; when X.sup.2 is S, n=0. In some embodiments, X.sup.3 is N, and p=1. In some embodiments, R.sup.5 is absent. In some embodiments, L is C.sub.1-C.sub.12 alkylene which is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, for example, L is (CH.sub.2).sub.q, wherein q is an integer of from 1 to 12, such as an integer of from 1 to 6. In some embodiments, when m=1, R.sup.6 is hydrogen. In some embodiments, when n=1, R.sup.7 is hydrogen. In some embodiments, R.sup.8 is hydrogen.

[0080] Preferably, in step (3), the third reaction is carried out in the presence of a base as an acid-binding agent.

[0081] In some embodiments, the present invention provides a method for preparing the amino lipid compound of Formula I′, comprising the steps of:

[0082] (1) performing a first reaction between cyanuric chloride and a compound represented by R.sup.1—X.sup.1′H at a temperature of −40° C. to 30° C. in the presence of a base as an acid-binding agent to obtain a first intermediate of Formula I′-1;

##STR00013##

[0083] (2) with or (preferably) without separating the first intermediate, performing a second reaction between the first intermediate and a compound represented by R.sup.2—X.sup.2′H at room temperature or under heating condition in the presence of a base as an acid-binding agent to obtain a second intermediate of Formula I′-2;

##STR00014##

[0084] (3) with or (preferably) without separating the second intermediate, performing a third reaction between the second intermediate and a diamine represented by H.sub.2N—(CH.sub.2).sub.q—NR.sup.3R.sup.4 under heating condition to obtain the amino lipid compound of Formula I′;

[0085] wherein the definitions of X.sup.1′, X.sup.2′, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and q are the same as the definitions thereof in the above description of the amino lipid compound of Formula I′.

[0086] Preferably, in step (3), the third reaction is carried out in the presence of a base as an acid-binding agent.

[0087] In some embodiments, the present invention provides a method for preparing the amino lipid compound of Formula I″ described above,

##STR00015##

[0088] comprising the steps of:

[0089] (1) performing a first reaction between cyanuric chloride with a compound represented by R.sup.1—SH at a temperature of −40° C. to 30° C. in the presence of a base as an acid-binding agent to obtain a first intermediate of Formula I″-1;

[0090] (2) with or (preferably) without separating the first intermediate, performing a second reaction between the first intermediate and a compound represented by R.sup.2—SH at room temperature or under heating condition in the presence of a base as an acid-binding agent to obtain a second intermediate of Formula I″-2;

##STR00016##

[0091] (3) with or (preferably) without separating the second intermediate, performing a third reaction between the second intermediate and a hydroxylamine represented by HO—(CH.sub.2).sub.q—NR.sup.3R.sup.4 at room temperature or under heating condition in the presence of a base as an acid-binding agent to obtain the amino lipid compound of Formula I″;

[0092] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and q are the same as the definitions thereof in the above description of the amino lipid compound of Formula I″.

[0093] In preferred embodiments of any of the methods described above, the first reaction is carried out at a temperature less than 20° C. (for example, less than 15° C., less than 10° C., less than 5° C., less than 0° C., less than −10° C., or less than −20° C., without particular limitation to the lower limit of the reaction temperature) and greater than −40° C. (for example, greater than −35° C., or preferably equal to or greater than −30° C.).

[0094] As used herein, the term “room temperature” refers to the normal temperature at atmospheric pressure, and may refer to a temperature ranging from 0° C. to 30° C., from 0° C. to 25° C., from 0° C. to 20° C., from 5° C. to 30° C., from 5° C. to 20° C., from 10° C. to 30° C., from 10° C. to 25° C., from 15° C. to 30° C., or from 15° C. to 25° C.

[0095] As used herein, the term “heating condition” specifically refers to heating to a temperature ranging from 50° C. to 120° C., from 50° C. to 110° C., from 50° C. to 80° C., from 60° C. to 120° C., from 60° C. to 110° C., from 60° C. to 100° C., from 70° C. to 120° C., from 70° C. to 100° C., or from 70° C. to 90° C.

[0096] As used herein, the term “base” can particularly be a base compound commonly used in the art, such as but not limited to organic bases, such as triethylamine, DIPEA, pyridine, DMAP; or inorganic bases, such as sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate.

[0097] Preferably, q is an integer of from 1 to 8, preferably an integer of from 1 to 6; more preferably, q is an integer of from 1 to 4, such as 1, 2, 3 or 4.

[0098] In some embodiments, the present invention provides a method for preparing an amino lipid compound of Formula II which can be carried out according to the following Equation 1:

##STR00017##

[0099] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X.sup.2 are the same as the definitions thereof in the above description of the method for preparing the amino lipid compound of Formula I.

[0100] In some embodiments, the present invention provides a method for preparing an amino lipid compound of Formula III which can be carried out according to the following Equation 2:

##STR00018##

[0101] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X.sup.2 are the same as the definitions thereof in the above description of the method for preparing the amino lipid compound of Formula I.

[0102] In some embodiments, the present invention provides a method for preparing an amino lipid compound of Formula IV which can be carried out according to the following Equation 3:

##STR00019##

[0103] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.2 and q are the same as the definitions thereof in the above description of the amino lipid compound of Formula I;

[0104] preferably, X.sup.2 is selected from the group consisting of O, S, S═O, S(═O).sub.2 and S—S, preferably O or S, and more preferably S.

[0105] In some embodiments, the present invention provides a method for preparing an amino lipid compound of Formula V which can be carried out according to the following Equation 4:

##STR00020##

[0106] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.2 and q are the same as the definitions thereof in the above description of the amino lipid compound of Formula I;

[0107] preferably, X.sup.2 is selected from the group consisting of O, S, S═O, S(═O).sub.2 and S—S, preferably O or S, and more preferably S.

[0108] It can be seen that the method for preparing the amino lipid compound according to the present invention is very universal, and can be used for rapid synthesis of amino lipid compound library and for rapid cell-based screening experiments at a low cost.

[0109] In another aspect, the present invention provides a use of the amino lipid compound according to any one of the formulae I, I′, II, III, IV and V for the preparation of lipid particles.

[0110] In another aspect, the present invention provides lipid particles comprising the amino lipid compound according to the present invention as described above.

[0111] Due to the long nonpolar residues contained in the amino lipid compound of the present invention, all the obtained compounds have hydrophobic characteristic, and simultaneously have hydrophilic characteristic due to the amine group. This amphoteric characteristic can be useful for forming lipid particles, such as lipid nanoparticles, lipid bilayers, micelles, liposomes, etc.

[0112] Within the scope of the present invention, the term “lipid particle” means nano-sized substances prepared by placing amino lipid compounds in an aqueous solution. These particles are particularly lipid nanoparticles, bilayered lipid vesicles (liposomes), multilayered vesicles or micelles.

[0113] In a preferred embodiment of the present invention, the lipid particles are liposomes containing the amino lipid compound according to the present invention as described above.

[0114] Within the scope of the present invention, liposomes are micro vesicles consisting of bilayers of lipid amphiphilic molecules surrounding aqueous compartments.

[0115] The formation of liposome is not a spontaneous process, lipid vesicles are formed firstly when lipids are added to water, thus forming a bilayer or a series of bilayers, each being separated by water molecules. Liposomes can be formed by ultrasonic treatment of lipid vesicles in water.

[0116] Within the scope of the present invention, the term “lipid bilayer” means a thin film formed by two layers of lipid molecules. The term “micelle” means an aggregate of surfactant molecules dispersed in a liquid colloid. Typical micelles in an aqueous solution form aggregates with the hydrophilic head regions upon contact with water, and chelate the hydrophobic single tail regions at the center of the micelles.

[0117] Within the scope of the present invention, the term “cell” means a general term, and includes the culture of individual cells, tissues, organs, insect cells, avian cells, fish cells, amphibian cells, mammalian cells, primary cells, continuous cell lines, stem cells and/or genetically engineered cells (such as recombinant cells expressing heterologous polypeptides or proteins). Recombinant cells include, for example, cells expressing heterologous polypeptides or proteins such as growth factors or blood factors.

[0118] In some preferred embodiments, the lipid particles or liposomes further contain one or more of a helper lipid, a sterol and a bioactive agent.

[0119] For example, in some embodiments, the lipid particles or liposomes contain a helper lipid. In preferred embodiments, the helper lipid is a non-cationic lipid. In more preferred embodiments, the helper lipid is a non-cationic phospholipid. Within the scope of the present invention, a non-cationic lipid can contain a cationic functional group (for example, ammonium), but should contain anionic functional group to at least neutralize the molecule. The total of all functional groups in the lipid molecule should be non-cationic. Liposomes consisting of the mixture of the amino lipid according to the present invention and a non-cationic (neutral) phospholipid are most effective for delivering nucleic acids into cells. In even more preferred embodiments, the non-cationic lipid is DOPE, DSPC or a combination thereof. In some preferred embodiments, the molar ratio of the amino lipid compound to the helper lipid in the lipid particles is about (2 to 10):1, preferably about (3 to 8):1, more preferably about (4 to 6):1, such as about 4:1, about 4.5:1 or about 5:1.

[0120] In some alternative or further embodiments, the lipid particles or liposomes comprise a sterol. Sterols, such as cholesterol, are natural components in cell membranes. It can be useful for stabilizing the particles and helping integration with cell membranes. The sterol may be one or more selected from the group consisting of cholesterol, sitosterol, stigmasterol and ergosterol, preferably cholesterol. In some preferred embodiments, the molar ratio of the amino lipid compound to the sterol in the lipid particles is about (1 to 1.5):1, preferably about (1 to 1.4):1, such as about (1 to 1.3):1.

[0121] In some alternative or further embodiments, the lipid particles or liposomes contain a bioactive agent. Within the scope of the present invention, bioactive agents are substances that have biological effects when introduced into cells or hosts, for example, by stimulating immune responses or inflammatory responses, by exerting enzyme activity or by complementary mutations, etc. The bioactive agent is particularly a nucleic acid, a peptide, a protein, an antibody and a small molecule. The term “lipid particle drug” can be used when liposomes are used to wrap a drug into lipid bilayers or into the inner aqueous space in the liposomes.

[0122] In the most preferred embodiments, the bioactive agent is a nucleic acid, including but not limited to messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small interfering RNA (siRNA) and small nuclear RNA (snRNA). In some other preferred embodiments, the bioactive agent is selected from the group consisting of an antitumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, an antigen or a fragment thereof, a protein, a peptide, a polypeptide, a polypeptoid, a vaccine and a small molecule, and mixtures thereof.

[0123] In some other embodiments, the lipid particles or liposomes further contain at least one polyethylene glycol (PEG)-lipid. PEG lipids contribute to protect particles and their contents from degradation in vitro or in vivo. In addition, PEG forms a protective layer on the liposome surface, and increases the circulation time in vivo. It can be used in the delivery of liposome drugs (PEG-liposome). Preferably, the PEG-lipid can be one or more selected from PEG1000-DMG, PEG5000-DMG, PEG2000-DMG and PEG2000-DSPE, preferably PEG2000-DMG In some preferred embodiments, the molar ratio of the amino lipid compound to the PEG-lipid in the lipid particles is about (9 to 42):1, preferably about (12 to 38):1, more preferably about (16 to 36):1, such as about (18 to 34):1.

[0124] The lipid particles or liposomes according to the present invention have excellent performances in encapsulating bioactive agents. The lipid particles or liposomes containing a bioactive agent can be used to deliver any of a variety of therapeutic agents into a cell. The present invention includes the use of the lipid particles (particularly, liposomes) as described above for delivering a bioactive agent into a cell. The present invention also provides a method for delivering a bioactive agent into a cell, comprising contacting lipid particles or liposomes containing the bioactive agent according to the present invention with the cell.

[0125] As shown above, the lipid particles or liposomes containing the amino lipid compound of the present invention is suitable for delivering a bioactive agent into a cell. Specific characteristics of liposomes imparted by various amino lipid compounds synthesized by the general synthesis method can be screened. The important characteristics are, e.g., transfection efficiency, cytotoxicity, adhesion of agents to be delivered into cells, stability of liposomes, size of liposomes, etc. The method of the invention can be used to form specific adaptive liposomes for specific applications.

[0126] For example, lipid particles or liposomes can be used to transfect multicellular tissues or organs. Therefore, the present invention also provides a method for transfecting a cell, a multicellular tissue or organ, comprising contacting lipid particles or liposomes containing the nucleic acid according to the present invention with the cell. This provides patients with the possibility for new therapeutic treatment.

[0127] According to the present invention, patients can be any mammal, preferably selected from mice, rats, pigs, cats, dogs, horses, goats, cows and monkeys and/or others. In some preferred embodiments, the patient is human.

[0128] In another aspect, the present invention still provides a use of lipid particles or liposomes comprising any one of the amino lipid compounds of formulae I, I′, I″, II, III, IV and V as a medicament. In another aspect, the present invention still provides a use of the lipid particles or liposomes comprising any one of the amino lipid compounds of formulae I, I′, I″, II, III, IV and V in the preparation of a medicament. For example, in some embodiments, the lipid particles are used as vectors for encapsulating a bioactive agent.

[0129] Particularly, the lipid particles or liposomes, or the medicament can be administered to patients for gene therapy, gene vaccination, antisense therapy or a therapy by RNA interference. Specific applications include but are not limited to:

[0130] (1) The lipid particles of the present invention can deliver nucleic acids for gene therapy. Exogenous genes are introduced into target cells through the amino lipid of the present invention to correct or remedy diseases caused by defective and abnormal genes, so as to achieve the therapeutic purpose. Among them, also included is the application of such technologies as transgene, that is, exogenous genes are inserted into appropriate recipient cells of a patient by gene transfer technology, so that the products produced by the exogenous genes can treat a certain disease, such as common lung cancer, gastric cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphatic cancer, hematologic cancer, prostate cancer, etc. Gene-edited nucleic acid substances can also be introduced for the treatment of various genetic diseases, such as hemophilia, thalassemia, Gaucher disease, etc.

[0131] (2) The lipid particles of the present invention can be used in vaccination. The lipid particles or liposomes of the present invention can be used for delivering antigens or nucleic acids encoding antigens. The lipid particles of the present invention can also be used for the initiation of immune responses against various antigens which are used for treating and/or preventing various disorders such as cancer, allergy, toxicity and pathogens (for example, viruses, bacteria, fungi and other pathogenic organisms) infection.

[0132] The present invention also provides a method for gene therapy, gene vaccination, antisense therapy or a therapy by RNA interference, comprising administering to a patient in need thereof lipid particles or liposomes of the present invention containing a bioactive agent (for example, a desired nucleic acid or antigen).

[0133] The lipid particles of the present invention can be used for preparing a medicament for nucleic acid transfer. Preferably, the nucleic acid is RNA, messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (Mirna), transfer RNA (tRNA), small interfering RNA (siRNA) and small nuclear RNA (snRNA).

[0134] Encapsulation of non-bioactive agents is also one purpose of the lipid particles or liposomes of the present invention. Therefore, the present invention also provides such lipid particles or liposomes comprising a non-bioactive agent. Examples of non-bioactive agent include, but are not limited to, antioxidants, pigments, dyes, perfumes and flavoring agents, such as those used in cosmetics. It is expected that the lipid particles or liposomes according to the present invention also have excellent performances in encapsulating non-bioactive agents.

[0135] The present invention also includes the following embodiments:

[0136] 1. An amino lipid compound which is a compound represented by the following formula I:

##STR00021##

[0137] wherein R.sup.1 and R.sup.2 are the same or different from each other, and are each independently selected from the group consisting of C.sub.6-C.sub.24 alkyl, C.sub.6-C.sub.24 alkenyl, C.sub.6-C.sub.24 alkynyl and C.sub.4-C.sub.24 acyl, wherein the C.sub.6-C.sub.24 alkyl, the C.sub.6-C.sub.24 alkenyl, the C.sub.6-C.sub.24 alkynyl and the C.sub.4-C.sub.24 acyl are optionally substituted with C.sub.1-C.sub.6hydrocarbyl;

[0138] X.sup.1, X.sup.2 and X.sup.3 are the same or different from one another, and are each independently selected from the group consisting of C, N, O, S, S═O, S(═O).sub.2 and S—S;

[0139] when X.sup.1 is C, m=2, and two R.sup.6 are the same or different from each other; when X.sup.1 is N, m=1; when X.sup.1 is O, S, S═O, S(═O).sub.2 or S—S, m=0;

[0140] when X.sup.2 is C, n=2, and two R.sup.7 are the same or different from each other; when X.sup.2 is N, n=1; when X.sup.2 is O, S, S═O, S(═O).sub.2 or S—S, n=0;

[0141] when X.sup.3 is C, p=2, and two R.sup.8 are the same or different from each other; when X.sup.3 is N, p=1; when X.sup.3 is O, S, S═O, S(═O).sub.2 or S—S, p=0;

[0142] R.sup.3 and R.sup.4 are the same or different from each other, and are each independently selected from the group consisting of C.sub.1-C.sub.12 alkyl, C.sub.2-C.sub.12 alkenyl and C.sub.2-C.sub.12 alkynyl, wherein the C.sub.1-C.sub.12 alkyl, the C.sub.2-C.sub.12 alkenyl and the C.sub.2-C.sub.12 alkynyl are optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, or R.sup.3 and R.sup.4 bind to each other to form an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from nitrogen, sulfur, and oxygen;

[0143] R.sup.5 is absent, or R.sup.5 is hydrogen or C.sub.1-C.sub.12 alkyl to provide a quaternary amine;

[0144] R.sup.6, R.sup.7, R.sup.8 are hydrogen or C.sub.1-C.sub.12 alkyl;

[0145] L is C.sub.1-C.sub.12 alkylene, C.sub.2-C.sub.12 alkenylene or C.sub.2-C.sub.12 alkynylene, wherein the C.sub.1-C.sub.12 alkylene, the C.sub.2-C.sub.12 alkenylene and the C.sub.2-C.sub.12 alkynylene are optionally substituted with one or more substituents selected from the group consisting of hydrocarbyl, carboxyl, acyl and alkoxy, or L is an optionally substituted 4-10 membered heterocycle containing heteroatoms selected from nitrogen, sulfur, and oxygen.

[0146] 2. The amino lipid compound according to item 1, wherein:

[0147] X.sup.1 is C, R.sup.6 is H, and m=2; or X.sup.1 is N, R.sup.6 is H, and m=1; or X.sup.1 is O, S, S═O, S(═O).sub.2 or S—S, and m=0;

[0148] X.sup.2 is C, R.sup.7 is H, and n=2; or X.sup.2 is N, R.sup.7 is H, and n=1; or X.sup.2 is O, S, S═O, S(═O).sub.2 or S—S, and n=0;

[0149] X.sup.3 is C, R.sup.8 is H, and p=2; or X.sup.3 is N, R.sup.8 is H, and p=1; or X.sup.3 is O, S, S═O, S(═O).sub.2 or S—S, and p=0.

[0150] 3. The amino lipid compound according to item 1, wherein:

[0151] R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.24 alkyl;

[0152] X.sup.1 is N, R.sup.6 is H, and m=1; or X.sup.1 is S, and m=0;

[0153] X.sup.2 is N, R.sup.7 is H, and n=1; or X.sup.2 is S, and n=0;

[0154] X.sup.3 is N, R.sup.8 is H, and p=1;

[0155] R.sup.3 and R.sup.4 are the same or different from each other, and are each independently C.sub.1-C.sub.12 alkyl, wherein the C.sub.1-C.sub.12 alkyl is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl, or R.sup.3 and R.sup.4 bind to each other to form an optionally substituted 4-10 membered heterocycle containing 1 to 6 heteroatoms selected from nitrogen, sulfur, and oxygen;

[0156] R.sup.5 is absent.

[0157] 4. The amino lipid compound according to any one of items 1 to 3, wherein L is C.sub.1-C.sub.4 alkylene, wherein the C.sub.1-C.sub.4 alkylene is optionally substituted with C.sub.1-C.sub.6 hydrocarbyl.

[0158] 5. The amino lipid compound according to any one of items 1 to 3, wherein R.sup.1 and R.sup.2 are the same or different from each other, and are each independently C.sub.6-C.sub.18 alkyl.

[0159] 6. The amino lipid compound according to item 1, wherein:

[0160] m=0, n=0, p=0,

[0161] R.sup.1—X.sup.1— and R.sup.2—X.sup.2— are the same or different from each other, and are each independently one selected from S6, S7, S8, S9, S10, S11, S12, S14, S15, S16, S18, N6, N7, N8, N9, N11, N12, N13, N15, N16, N18, .sup.2N.sub.12 described above;

[0162] —X.sup.3-L-N(R.sup.3)(R.sup.4)(R.sup.5) is one selected from D1, D2, D3, D4, D5, D6, D7, D8, D9, D10 described above.

[0163] 7. A method for preparing the amino lipid compound according to any one of items 1-6, comprising the steps of:

[0164] (1) performing a first reaction between cyanuric chloride and a compound represented by R.sup.1—X.sup.1H at a temperature of −30° C. to 30° C. in the presence of a base as an acid-binding agent to obtain a first intermediate, wherein X.sup.1 is NH or S;

[0165] (2) performing a second reaction by adding a compound represented by R.sup.2—X.sup.2H without separating the first intermediate, at room temperature or under heating condition in the presence of a base as an acid-binding agent to obtain a second intermediate, wherein X.sup.2 is NH or S;

[0166] (3) performing a third reaction by adding a diamine represented by H.sub.2N—(CH.sub.2).sub.q—NR.sup.3R.sup.4 without separating the second intermediate, under heating condition to obtain the amino lipid compound;

[0167] wherein q is an integer of from 1 to 12, and the definitions of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are the same as the definitions thereof in any one of items 1 to 6.

[0168] 8. A method for preparing the amino lipid compound according to the present invention, which can be carried out according to the following Equation 1:

##STR00022##

[0169] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.2 are the same as the definitions thereof in the above description of the method for preparing the amino lipid compound.

[0170] 9. A method for preparing the amino lipid compound according to the present invention, which can be carried out according to the following Equation 2:

##STR00023##

[0171] wherein the definitions of R.sup.1, R.sup.2, R.sup.3, R.sup.4, X.sup.2 are the same as the definitions thereof in the above description of the method for preparing the amino lipid compound.

[0172] 10. Use of the amino lipid compound according to any one of items 1 to 6 for preparing lipid particles, wherein the lipid particles are lipid nanoparticles, liposomes, multilayered vesicles or micelles; more preferably, the lipid particles are lipid nanoparticles.

[0173] 11. Lipid particles comprising the amino lipid compound according to any one of items 1 to 6; preferably, the lipid particles are lipid nanoparticles, liposomes, multilayered vesicles or micelles; more preferably, the lipid particles are lipid nanoparticles.

[0174] 12. The lipid particles according to item 11, further containing one or more of a helper lipid, a sterol and a bioactive agent;

[0175] preferably, the helper lipid is a non-cationic lipid; more preferably, the helper lipid is a non-cationic phospholipid; and even more preferably, the non-cationic lipid is DOPE;

[0176] preferably, the sterol is cholesterol;

[0177] preferably, the bioactive agent is one or more of a nucleic acid, an antitumor agent, an antibiotic, an immunomodulator, an anti-inflammatory agent, an agent acting on the central nervous system, an antigen or fragments thereof, a peptide, a protein, an antibody, a vaccine and a small molecule; more preferably, the nucleic acid is RNA, messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small interfering RNA (siRNA) and small nuclear RNA (snRNA).

[0178] 13. Use of the lipid particles according to item 11 or 12 in the preparation of a medicament for gene therapy, gene vaccination, antisense therapy or a therapy by RNA interference;

[0179] preferably, the gene therapy is useful for the treatment of a cancer and a genetic disease; more preferably, the cancer is one or more of lung cancer, gastric cancer, liver cancer, esophageal cancer, colon cancer, pancreatic cancer, brain cancer, lymphatic cancer, hematologic cancer or prostate cancer, and the genetic disease is one or more of hemophilia, thalassemia and Gaucher disease;

[0180] preferably, the gene vaccination is c for the treatment of cancer, allergy, toxicity and pathogen infection; more preferably, the pathogen is one or more of viruses, bacteria or fungi.

[0181] 14. Use of the lipid particles according to item 11 or 12 in the preparation of a medicament for nucleic acid transfer, preferably, the nucleic acid is RNA, messenger RNA (mRNA), antisense oligonucleotide, DNA, plasmid, ribosomal RNA (rRNA), microRNA (miRNA), transfer RNA (tRNA), small interfering RNA (siRNA) and small nuclear RNA (snRNA).

Beneficial Effects

[0182] The amino lipid compound of the present invention is characterized in having functional groups of a wide diversity and a large quantity; the preparation method of the amino lipid compound has advantages such as easily available raw materials, mild reaction conditions, excellent reaction selectivity, high reaction yield, low equipment requirements and simple operations; and the preparation method of the present invention is very universal, and can be used for rapid synthesis of libraries of ionizable amino lipid compounds and for rapid cell-based screening experiments at a low cost.

[0183] The amino lipid compound provided by the present invention has such functional groups that include various types and combination modes, and can be conveniently adapted to the delivery of different nucleic acid substances to different cells through conventional screening with regard to transfection efficiency, cytotoxicity, adhesion of agents to be delivered to cells, stability of lipid particles, size of lipid particles and other characteristics, thereby improving the specificity and effectiveness of the delivery system.

[0184] The amino lipid compound of the present invention can be synthesized by way of combinatorial chemistry with high throughput and high efficiency, and the synthesis method is simple and high-yield.

[0185] Lipid particles or liposomes comprising the amino lipid compound of the present invention have excellent performances in encapsulating bioactive agents, and can be used for the delivery of bioactive agents, especially poorly water-soluble drugs or easily decomposable or degradable active agents (such as nucleic acids) to improve the bioavailability and efficacy thereof.

[0186] To make the objects, technical solutions and advantages of the present invention clearer, the present invention will be described below with reference to specific examples. The described examples are part of the embodiments of the present invention, but not all of them.

[0187] Based on the examples of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative work are within the scope of the present invention.

EXAMPLES

[0188] Unless otherwise specified, all chemical reagents used in the examples are analytically pure and purchased from TCI, Aladdin, J&K, etc.

Example 1: Synthesis of Amino Lipid Compounds

[0189] In order to systematically study the relationship between structure such as the length of alkyl chains, the combination modes of alkyl chains, ionizable head groups, and transfection capacity, 11 linear alkylthiols with chains of 6-18 carbons (S6-S18), 11 alkylamines with chains of 6-24 carbons (N6-.sup.2N.sub.12), and 10 diamines with different structures from one another (D1-D6) were selected. Libraries of 2530 compounds comprising both two alkyl chains and ionizable head groups were synthesized by way of combinatorial chemistry with high throughput, the synthesis route being as follows:

[0190] (a) Triazine as a Linker

##STR00024##

[0191] (b) Typical Example

##STR00025##

[0192] (c) Synthetic Building Blocks

TABLE-US-00001 Diamines [00026] D1 [00027] D2 [00028] D3 [00029] D4 [00030] D5 [00031] D6 [00032] D7 [00033] D8 [00034] D9 [00035] D10 Thiols and amines [00036] [00037] S6  n1 = 6  N6  n2 = 6  S7  n1 = 7  N7  n2 = 7  S8  n1 = 8  N8  n2 = 8  S9  n1 = 9  N9  n2 = 9  S10 n1 = 10 N11 n2 = 11 S11 n1 = 11 N12 n2 = 12 S12 n1 = 12 N13 n2 = 13 S14 n1 = 14 N15 n2 = 15 S15 n1 = 15 N16 n2 = 16 S16 n1 = 16 N18 n2 = 18 S18 n1 = 18 .sup.2N.sub.12 (n-C.sub.12H.sub.25).sub.2NH

[0193] (d) Compound Libraries

##STR00038##

[0194] wherein n3=1, 2 or 3; —NRR represents the dialkylamino or cyclic amino moiety in the diamines D1 to D10 described above; and R.sup.1 and R.sup.2 are as defined above.

[0195] The synthesized compounds have one of the structures shown in the following table I:

TABLE-US-00002 TABLE I Synthesized compounds Compound SzNxDy Compound SzSzDy Compound NxNxDy [00039] [00040] [00041]

[0196] wherein each Sz independently represents a group selected from S6 to S12, S14 to S16 and S18 listed in Table II below;

[0197] each Nx independently represents a group selected from N6 to N9, N11 to N13, N15, N16, N18 and .sup.2N.sub.12 listed in Table II below; and

[0198] each Dy independently represents a group selected from D1 to D10 listed in the following Table II:

TABLE-US-00003 TABLE II Group Sz Group Nx Group Dy S6 —S—(CH.sub.2).sub.6—H N6 —NH—(CH.sub.2).sub.6—H D1 [00042] S7 —S—(CH.sub.2).sub.7—H N7 —NH—(CH.sub.2).sub.7—H D2 [00043] S8 —S—(CH.sub.2).sub.8—H N8 —NH—(CH.sub.2).sub.8—H D3 [00044] S9 —S—(CH.sub.2).sub.9—H N9 —NH—(CH.sub.2).sub.9—H D4 [00045] S10 —S—(CH.sub.2).sub.10—H N11 —NH—(CH.sub.2).sub.11—H D5 [00046] S11 —S—(CH.sub.2).sub.11—H N12 —NH—(CH.sub.2).sub.12—H D6 [00047] S12 —S—(CH.sub.2).sub.12—H N13 —NH—(CH.sub.2).sub.13—H D7 [00048] S14 —S—(CH.sub.2).sub.14—H N15 —NHS—(CH.sub.2).sub.15—H D8 [00049] S15 —S—(CH.sub.2).sub.15—H N16 —NH—(CH.sub.2).sub.16—H D9 [00050] S16 —S—(CH.sub.2).sub.16—H N18 —NH—(CH.sub.2).sub.18—H D10 [00051] S18 —S—(CH.sub.2).sub.18—H .sup.2N.sub.12 —N—((CH.sub.2).sub.12—H).sub.2

[0199] The mass spectrum ([M+H].sup.+) data measured for the synthesized compounds are shown in Table III below:

TABLE-US-00004 TABLE III D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 S6N6 383.4 425.3 409.3 423.4 438.4 397.3 411.4 439.3 452.4 423.4 S6N7 397.3 439.3 423.3 437.4 452.4 411.3 425.4 453.3 466.4 437.5 S6N8 411.4 453.3 437.4 451.4 466.6 425.4 439.4 467.3 480.6 451.4 S6N9 425.3 467.4 451.3 465.4 480.4 439.3 453.4 481.3 494.4 465.4 S6N11 453.3 495.3 479.3 493.4 508.4 467.3 481.5 509.4 522.4 493.4 S6N12 467.4 509.3 493.4 507.4 522.4 481.3 495.4 523.3 536.4 507.6 S6N13 481.3 523.5 507.3 521.5 536.4 495.3 509.4 537.5 550.6 521.4 S6N15 509.6 551.3 535.5 549.4 564.4 523.3 537.5 565.3 578.4 549.4 S6N16 523.3 565.3 549.3 563.4 578.6 537.3 551.4 579.5 592.4 563.4 S6N18 551.3 593.3 577.3 591.4 606.4 565.3 579.4 607.3 620.4 591.6 S6.sup.2N12 635.6 677.4 661.4 675.5 690.5 649.6 663.5 691.4 704.5 675.5 S7N6 397.3 439.6 423.7 437.4 452.4 411.3 425.4 453.3 466.4 437.6 S7N7 411.3 453.3 437.3 451.4 466.4 425.3 439.4 467.3 480.6 451.4 S7N8 425.5 467.3 451.3 465.4 480.6 439.3 453.5 481.3 494.4 465.4 S7N9 439.3 481.3 465.3 479.4 494.4 453.5 467.4 495.5 508.4 479.4 S7N11 467.5 509.3 493.7 507.7 522.4 481.3 495.4 523.3 536.4 507.4 S7N12 481.3 523.3 507.6 521.4 536.7 495.3 509.6 537.3 550.6 521.4 S7N13 495.6 537.6 521.3 535.4 550.4 50963 523.4 551.3 564.4 535.4 S7N15 523.3 565.3 549.3 563.4 578.4 537.3 551.4 579.3 592.4 563.4 S7N16 537.3 579.3 563.3 577.4 592.4 551.3 565.4 593.3 606.4 577.4 S7N18 565.3 607.3 591.3 605.4 620.4 579.3 593.4 621.3 634.4 605.4 S7.sup.2N12 649.4 691.4 675.4 689.5 704.5 663.4 677.5 705.4 718.5 689.5 S8N6 411.3 453.3 437.3 451.4 466.4 425.3 439.4 467.3 480.4 451.4 S8N7 425.3 467.3 451.3 465.4 480.6 439.3 453.4 481.3 494.4 465.4 S8N8 439.8 481.3 465.3 479.4 494.4 453.6 467.4 495.3 508.6 479.4 S8N9 453.3 495.8 479.8 493.6 508.4 467.3 481.5 509.5 522.4 493.6 S8N12 495.7 537.3 521.3 535.4 550.6 509.3 523.4 551.3 564.4 535.4 S8N13 509.3 551.3 535.6 549.4 564.4 523.3 537.6 565.3 578.5 549.6 S8N15 537.3 579.3 563.3 577.4 592.4 551.3 565.4 593.3 606.4 577.4 S8N16 551.3 593.3 577.3 591.4 606.4 565.3 579.4 607.3 620.4 591.4 S8N18 579.6 621.3 605.3 619.4 634.4 593.3 607.4 635.3 648.4 619.4 S8.sup.2N12 663.4 705.4 689.4 703.5 718.5 677.4 691.5 719.4 732.5 703.5 S9N6 425.3 467.3 451.3 465.4 480.7 439.3 453.4 481.3 494.4 465.6 S9N7 439.3 481.3 465.3 479.6 494.4 453.3 467.4 495.3 508.4 479.4 S9N8 453.6 495.3 479.3 493.4 508.4 467.3 481.4 509.6 522.4 493.4 S9N9 467.3 509.3 493.3 507.4 522.4 481.3 495.4 523.3 536.4 507.4 S9N11 495.3 537.3 521.6 535.4 550.4 509.3 523.4 551.3 564.4 535.6 S9N12 509.3 551.6 535.3 549.4 564.4 523.3 537.4 565.3 578.4 549.4 S9N13 523.6 565.6 549.3 563.4 578.4 537.3 551.4 579.3 592.4 563.4 S9N15 551.3 593.3 577.3 591.4 606.4 565.3 579.4 607.3 620.4 591.4 S9N16 565.3 607.3 591.3 605.4 620.4 579.3 593.4 621.3 634.4 605.4 S9N18 593.3 635.3 619.6 633.4 648.4 607.3 621.4 649.3 662.4 633.4 S9.sup.2N12 677.4 719.4 703.4 717.5 732.5 691.4 705.5 733.4 746.5 717.5 S10N6 439.5 481.6 465.6 479.4 494.4 453.5 467.4 495.3 508.4 479.4 S10N7 453.3 495.3 479.3 493.5 508.4 467.3 481.4 509.3 522.4 493.4 S10N8 467.3 509.3 493.3 507.7 522.4 481.3 495.4 523.3 536.4 507.4 S10N9 481.3 523.3 507.3 521.4 536.4 495.5 509.4 537.3 550.4 521.4 S10N11 509.3 551.3 535.3 549.4 564.4 523.3 537.4 565.3 578.4 549.4 S10N12 523.3 565.3 549.3 563.4 578.4 537.3 551.4 579.3 592.4 563.4 S10N13 537.3 579.3 563.3 577.4 592.4 551.3 565.4 593.3 606.7 577.7 S10N15 565.3 607.3 591.3 605.4 620.4 579.3 593.4 621.3 634.4 605.4 S10N16 579.3 621.3 605.3 619.4 634.4 593.3 607.4 635.6 648.4 619.4 S10N18 607.3 649.3 633.3 647.4 662.4 621.3 635.4 663.3 676.4 647.4 S10.sup.2N12 691.4 733.4 717.4 731.5 746.5 705.4 719.7 747.4 760.5 731.5 S11N6 453.3 495.3 479.3 493.4 508.4 467.3 481.4 509.3 522.4 493.4 S11N7 467.3 509.3 493.3 507.4 522.4 481.3 495.4 523.3 536.4 507.4 S11N8 481.3 523.3 507.3 521.4 536.4 495.3 509.4 537.3 550.4 521.4 S11N9 495.3 537.3 521.6 535.4 550.4 509.3 523.4 551.3 564.4 535.4 S11N11 523.3 565.3 549.3 563.4 578.6 537.3 551.4 579.3 592.4 563.4 S11N12 537.6 579.3 563.3 577.4 592.4 551.3 565.4 593.3 606.4 577.6 S11N13 551.3 593.3 577.3 591.4 606.4 565.3 579.4 607.3 620.4 591.4 S11N15 579.6 621.3 605.6 619.4 634.4 593.3 607.4 635.3 648.4 619.4 S11N16 593.3 635.3 619.3 633.4 648.4 607.3 621.4 649.3 662.4 633.4 S11N18 621.3 663.3 647.3 661.4 676.4 635.3 649.4 677.3 690.4 661.4 S11.sup.2N12 705.4 747.4 731.6 745.7 760.5 719.4 733.5 761.4 774.5 745.5 S12N6 467.3 509.3 493.3 507.4 522.4 481.3 495.4 523.3 536.4 507.4 S12N7 481.3 523.3 507.3 521.4 536.4 495.3 509.4 537.3 550.4 521.4 S12N8 495.3 537.3 521.3 535.4 550.4 509.3 523.4 551.3 564.4 535.4 S12N9 509.3 551.3 535.3 549.4 564.4 523.3 537.4 565.3 578.4 549.4 S12N11 537.3 579.3 563.3 577.5 592.7 551.3 565.4 593.3 606.4 577.4 S12N12 551.3 593.3 577.3 591.4 606.4 565.3 579.7 607.3 620.4 591.4 S12N13 565.3 607.3 591.3 605.4 620.4 579.3 593.4 621.3 634.4 605.4 S12N15 593.3 635.3 619.3 633.4 648.4 607.3 621.4 649.3 662.4 633.4 S12N16 607.3 649.3 633.3 647.4 662.4 621.3 635.4 663.3 676.4 647.4 S12N18 635.3 677.3 661.3 675.4 690.4 649.3 663.4 691.5 704.4 675.4 S12.sup.2N12 719.5 761.4 745.4 759.5 774.5 733.4 747.5 775.4 788.5 759.5 S14N6 495.3 537.3 521.3 535.4 550.4 509.3 523.4 551.3 564.5 535.5 S14N7 509.3 551.5 535.3 549.4 564.4 523.3 537.4 565.3 578.4 549.4 S14N8 523.5 565.3 549.3 563.4 578.4 537.5 551.4 579.3 592.4 563.4 S14N9 537.3 579.6 563.3 577.4 592.5 5516 565.4 593.6 606.6 577.4 S14N11 565.3 607.3 591.6 605.4 620.4 579.3 593.4 621.3 634.4 605.4 S14N12 579.5 621.3 605.3 619.4 634.4 593.3 607.4 635.3 648.4 619.4 S14N13 593.3 635.6 619.3 633.4 648.4 607.3 621.4 649.3 662.4 633.4 S14N15 621.3 663.3 647.3 661.4 676.4 635.3 649.4 677.3 690.4 661.4 S14N16 635.6 677.3 661.3 675.4 690.4 649.3 663.4 691.3 704.4 675.4 S14N18 663.3 705.3 689.3 703.4 718.4 677.3 691.4 719.3 732.4 703.6 S14.sup.2N12 747.4 789.4 773.4 787.5 802.5 761.4 775.6 803.4 816.5 787.5 S15N6 509.3 551.7 535.3 549.4 564.4 523.6 537.4 565.3 578.6 549.4 S15N7 523.7 565.3 549.3 563.4 578.4 537.3 551.4 5796 592.4 563.4 S15N8 537.3 579.3 563.3 577.4 592.4 551.3 565.4 593.3 606.4 577.4 S15N9 551.3 593.3 577.7 591.4 606.4 565.3 579.4 607.3 620.4 591.4 S15N11 579.7 621.3 605.3 619.7 634.6 593.3 607.7 635.3 648.8 619.9 S15N12 593.3 635.3 619.3 633.4 648.4 607.3 621.4 649.3 662.4 633.4 S15N13 607.5 649.3 633.3 647.7 662.4 621.3 635.4 663.3 676.4 647.4 S15N15 635.3 677.3 6615 675.4 690.4 649.3 663.4 691.3 704.4 675.4 S15N16 649.3 691.5 675.3 689.4 704.7 663.3 677.4 705.3 718.4 689.4 S15N18 677.3 719.3 703.3 717.4 732.4 691.3 705.4 733.3 746.4 717.4 S15.sup.2N12 761.4 803.4 787.4 801.5 816.5 775.4 789.5 817.4 830.5 801.5 S16N6 523.3 565.3 549.3 563.4 578.4 537.3 551.4 579.3 592.4 563.4 S16N7 537.3 579.3 563.7 577.4 592.4 551.3 565.4 593.3 606.4 577.4 S16N8 551.6 593.6 577.3 591.4 606.4 565.3 579.4 607.3 620.4 591.4 S16N9 565.3 607.3 591.5 605.6 620.4 579.3 593.4 621.3 634.4 605.4 S16N11 593.3 635.3 619.3 633.4 648.7 607.3 621.4 649.3 662.4 633.4 S16N12 607.3 649.3 633.3 647.4 662.4 621.3 635.4 663.3 676.4 647.4 S16N13 621.3 663.6 647.3 661.4 676.4 635.3 649.4 677.3 690.4 661.4 S16N15 649.3 691.3 675.6 689.4 704.4 663.7 677.4 705.3 718.4 689.4 S16N16 663.3 705.3 689.3 703.4 718.4 677.3 691.4 719.3 732.4 703.4 S16N18 691.3 733.3 717.3 731.4 746.4 705.3 719.4 747.3 760.4 731.4 S16.sup.2N12 775.4 817.4 801.4 815.5 830.5 789.4 803.5 831.7 844.7 815.5 S18N6 551.3 593.3 577.3 591.4 606.4 565.3 579.4 607.3 620.4 591.4 S18N7 565.3 607.3 591.3 605.4 620.4 579.3 593.4 621.3 634.4 605.8 S18N8 579.3 621.3 605.6 619.4 634.7 593.3 607.4 635.3 648.4 619.4 S18N9 593.3 635.3 619.3 633.4 648.4 607.5 621.6 649.7 662.8 633.8 S18N11 621.3 663.3 647.3 661.4 676.4 635.3 649.4 677.3 690.4 661.4 S18N12 635.3 677.3 661.3 675.4 690.4 649.3 663.4 691.3 704.4 675.4 S18N13 649.5 691.3 675.3 689.4 704.4 663.3 677.4 705.3 718.4 689.4 S18N15 677.3 719.3 703.3 717.4 732.4 691.3 705.4 733.3 746.4 717.4 S18N16 691.3 733.3 717.3 731.4 746.4 705.3 719.4 747.3 760.4 731.4 S18N18 719.3 761.6 745.3 759.4 774.4 733.3 747.4 775.3 788.4 759.4 S18.sup.2N12 803.4 845.4 829.7 843.7 858.5 817.4 831.5 859.4 872.5 843.5 S6S6 400.3 442.3 426.3 440.4 455.7 414.3 428.4 456.3 469.4 440.4 S6S7 414.3 456.3 440.3 454.4 469.4 428.3 442.4 470.3 483.4 454.4 S6S8 428.3 470.3 454.3 468.4 483.4 442.3 456.4 484.3 497.4 468.4 S6S9 442.3 484.3 468.3 482.4 497.4 456.3 470.4 498.3 511.4 482.4 S6S10 456.3 498.3 482.3 496.4 511.4 470.3 484.4 512.3 525.4 496.4 S6S11 470.3 512.3 496.3 521.4 525.4 484.3 484.3 526.5 539.4 510.4 S6S12 484.6 526.6 510.3 524.4 539.4 498.3 512.4 540.3 553.4 524.4 S6S14 512.3 554.3 538.5 552.4 567.4 526.3 540.4 568.3 581.4 552.4 S6S15 526.5 568.3 552.3 566.4 581.4 540.4 554.4 582.3 595.4 566.4 S6S16 540.3 582.3 566.3 580.4 595.4 554.3 568.4 596.3 609.4 580.4 S6S18 568.3 610.3 594.3 608.4 623.4 582.3 596.4 624.3 637.4 608.4 S7S7 428.5 470.3 454.3 468.4 483.4 442.3 456.4 484.3 497.4 468.4 S7S8 442.3 484.3 468.3 482.4 497.4 456.3 470.4 498.3 511.4 482.4 S7S9 456.3 498.3 482.3 496.4 511.4 470.3 484.4 512.3 525.4 496.4 S7S10 470.3 512.5 496.3 510.4 525.4 484.3 498.4 526.3 539.4 510.4 S7S11 484.3 526.3 510.3 524.4 539.4 498.3 512.4 540.3 553.4 524.4 S7S12 498.7 540.3 524.3 538.4 553.4 512.3 526.4 554.3 567.4 538.4 S7S14 526.3 568.3 552.3 566.4 581.4 540.3 554.4 582.3 595.4 566.4 S7S15 540.3 582.3 566.3 580.4 595.4 554.3 568.4 596.3 609.4 580.4 S7S16 554.6 596.3 580.3 594.4 609.4 568.3 582.4 610.3 623.4 594.4 S7S18 582.3 624.3 608.3 622.4 637.4 596.3 610.4 638.3 651.4 622.4 S8S8 456.8 498.3 482.3 496.4 511.4 470.3 484.4 512.3 525.4 496.4 S8S9 470.3 512.3 496.3 510.6 525.6 484.3 498.6 526.3 539.4 510.4 S8S10 484.7 526.3 510.3 524.4 539.4 498.3 512.4 540.3 553.8 524.7 S8S11 498.3 540.3 524.3 538.4 553.4 512.3 526.4 554.3 567.4 538.4 S8S12 512.3 554.3 538.3 552.4 567.4 526.3 540.4 568.3 581.4 552.4 S8S14 540.3 582.3 566.3 580.4 595.4 554.3 568.4 596.3 609.4 580.4 S8S15 554.3 596.3 580.3 594.4 609.4 568.3 582.4 610.3 623.4 594.4 S8S16 568.3 610.3 594.3 608.4 623.4 582.3 596.4 624.3 637.4 608.4 S8S18 596.3 638.3 622.3 636.4 651.4 610.3 624.4 652.3 665.4 636.4 S9S9 484.3 526.3 510.3 524.4 539.4 498.3 512.4 540.3 553.4 524.4 S9S10 498.3 540.7 524.6 538.4 553.4 512.3 526.4 554.3 567.4 538.4 S9S11 512.3 554.3 538.3 552.4 567.4 526.3 540.4 568.3 581.4 552.4 S9S12 526.3 568.3 552.3 566.4 581.4 540.3 554.4 582.3 595.4 566.4 S9S14 554.3 596.3 580.3 594.4 609.4 568.3 582.4 610.3 623.4 594.4 S9S15 568.3 610.6 594.3 608.5 623.4 582.5 596.6 624.3 637.4 608.4 S9S16 582.3 624.3 608.3 622.4 637.4 596.3 610.4 638.7 651.4 622.5 S9S18 610.3 652.3 636.3 650.4 665.4 624.3 638.4 666.3 679.4 650.4 S10S10 512.3 554.3 538.3 552.4 567.4 526.3 540.4 568.3 581.4 552.4 S10S11 526.3 568.3 552.3 566.4 581.4 540.3 554.4 582.3 595.4 566.4 S10S12 540.3 582.3 566.3 580.4 595.4 554.3 568.4 596.3 609.4 580.4 S10S14 568.3 610.6 594.3 608.4 623.4 582.3 596.4 624.3 637.4 608.4 S10S15 582.3 624.3 608.3 622.4 637.4 596.3 610.4 638.3 651.4 622.4 S10S16 596.3 638.3 622.3 636.4 651.4 610.3 624.4 652.3 665.4 636.4 S10S18 624.3 666.3 650.3 664.4 679.4 638.3 652.4 680.3 693.4 664.4 S11S11 540.5 582.3 566.5 580.4 595.4 554.3 568.4 596.3 609.4 580.4 S11S12 554.3 596.3 580.3 594.4 609.4 568.3 582.4 610.3 623.4 594.4 S11S14 582.3 624.5 608.3 622.4 637.4 596.3 610.4 638.3 651.4 622.4 S11S15 596.3 638.3 622.6 636.4 651.4 610.3 624.4 652.3 665.4 636.4 S11S16 610.3 652.3 636.3 650.7 665.4 624.3 638.4 666.3 679.4 650.4 S11S18 638.3 680.3 664.3 678.4 693.4 652.3 666.4 694.3 707.4 678.4 S12S12 568.3 610.5 594.3 608.4 623.6 582.7 596.4 624.3 637.4 608.4 S12S14 596.3 638.3 622.3 636.4 651.4 610.3 624.4 652.3 665.4 636.4 S12S15 610.3 652.3 636.3 650.4 665.4 624.3 638.4 666.3 679.4 650.4 S12S16 624.3 666.3 650.3 664.4 679.4 638.3 652.4 680.3 693.4 664.4 S12S18 652.3 694.3 678.3 692.4 707.4 666.3 680.8 708.9 721.4 692.4 S14S14 624.3 666.3 650.3 664.4 679.4 638.3 652.4 680.3 693.4 664.4 S14S15 638.3 680.6 664.3 678.4 693.4 652.5 666.4 694.3 707.4 678.4 S14S16 652.3 694.3 678.3 692.4 707.4 666.3 680.4 708.3 721.4 692.4 S14S18 680.4 722.3 706.3 720.8 735.7 694.3 708.4 736.3 749.4 720.4 S15S15 652.3 694.5 678.3 692.4 707.4 666.3 680.4 708.3 721.4 692.4 S15S16 666.3 708.3 692.3 706.4 721.4 680.3 694.4 722.3 735.4 706.4 S15S18 694.3 736.3 720.3 734.4 749.4 708.3 722.4 750.3 763.4 734.4 S16S16 680.3 722.3 706.3 720.4 735.4 694.3 708.4 736.3 749.4 720.4 S16S18 708.3 750.3 734.3 748.4 763.4 722.3 736.4 764.3 777.4 748.4 S18S18 736.3 778.3 762.3 776.4 791.4 750.3 764.4 792.3 805.4 776.4 N6N6 366.4 408.4 392.4 406.8 421.5 380.4 394.5 422.4 435.5 406.5 N6N7 380.4 422.4 406.4 420.5 435.5 394.4 408.5 436.4 449.5 420.5 N6N8 394.4 436.4 420.4 434.5 449.6 408.4 422.5 450.4 463.5 434.5 N6N9 408.4 450.4 434.4 448.5 463.5 422.4 436.5 464.4 477.5 448.5 N6N11 436.4 478.4 462.4 476.4 491.4 450.4 464.4 492.4 492.4 476.4 N6N12 450.4 492.4 476.4 490.5 505.5 464.4 478.5 506.4 519.5 490.5 N6N13 464.4 506.4 490.4 504.5 519.5 478.4 492.5 520.4 533.5 504.5 N6N15 492.4 534.4 518.4 532.5 547.5 506.4 520.5 548.4 561.5 532.5 N6N16 506.4 548.4 532.4 546.5 561.5 520.4 534.5 562.4 575.5 546.5 N6N18 534.4 576.4 560.4 574.5 589.5 548.4 562.5 590.4 603.5 574.5 N6.sup.2N12 618.5 660.5 644.5 658.6 673.6 632.5 646.6 674.5 687.6 658.6 N7N7 394.4 436.4 420.4 434.5 449.5 408.4 422.5 450.4 463.5 434.5 N7N8 408.4 450.4 434.4 448.5 463.5 422.4 436.5 464.4 477.5 448.5 N7N9 422.4 464.4 448.7 462.5 477.5 436.4 450.5 478.4 491.5 462.5 N7N11 450.4 492.4 476.4 490.5 505.5 464.4 478.5 506.4 519.5 490.5 N7N12 464.4 506.4 490.4 504.5 519.5 478.4 492.5 520.4 533.5 504.5 N7N13 478.4 520.4 504.4 518.5 533.5 492.4 506.5 534.4 547.5 518.5 N7N15 506.8 548.4 532.8 546.5 561.5 520.5 534.5 562.4 575.5 546.5 N7N16 520.4 562.4 546.4 560.5 575.5 534.4 548.5 576.4 589.5 560.5 N7N18 548.4 590.4 574.4 588.5 603.5 562.4 576.5 604.4 617.5 588.5 N7.sup.2N12 632.7 674.7 658.5 672.6 687.6 646.5 660.6 688.5 701.6 672.6 N8N8 422.4 464.8 448.4 462.5 477.5 436.4 450.5 478.4 491.5 462.5 N8N9 436.4 478.4 462.4 476.5 491.5 450.4 464.5 492.4 505.5 476.5 N8N11 464.7 506.4 490.4 504.5 519.5 478.4 492.5 520.4 533.5 504.5 N8N12 478.5 520.4 504.4 518.5 533.8 492.4 506.5 534.4 547.5 518.5 N8N13 492.4 534.7 518.4 532.5 547.5 506.4 520.5 548.4 561.5 532.5 N8N15 520.4 562.6 546.4 560.5 575.5 534.4 548.5 576.4 589.5 560.5 N8N16 534.4 576.8 560.4 574.5 589.5 548.4 562.5 590.4 603.5 574.5 N8N18 562.4 604.4 588.4 602.5 617.5 576.4 590.5 618.4 631.5 602.5 N8.sup.2N12 646.5 688.5 672.5 686.6 701.6 660.5 674.6 702.5 715.6 686.6 N9N9 450.4 492.4 476.4 490.5 505.5 464.4 478.5 506.4 519.5 490.5 N9N11 478.4 520.4 504.4 518.5 533.5 492.4 506.5 534.4 547.5 518.5 N9N12 492.4 534.4 518.7 532.5 547.5 506.4 520.5 548.4 561.5 532.5 N9N13 506.4 548.4 532.4 546.5 561.5 520.4 534.5 562.4 575.5 546.5 N9N15 534.4 576.4 560.4 574.9 589.5 548.4 562.5 590.4 603.5 574.5 N9N16 548.4 590.4 574.4 588.5 603.5 562.9 576.5 604.4 617.5 588.5 N9N18 576.8 618.4 602.4 616.5 631.5 590.4 604.5 632.4 645.9 616.5 N9.sup.2N12 660.5 702.5 686.9 700.6 715.6 674.5 688.6 716.5 729.6 700.6 N11N11 506.4 548.4 532.4 546.5 561.5 520.4 534.6 562.4 575.5 546.5 N11N12 520.4 562.4 546.4 560.5 575.5 534.4 548.5 576.4 589.5 560.5 N11N13 534.4 576.4 560.4 574.5 589.5 548.4 562.5 590.4 603.5 574.5 N11N15 562.4 604.4 588.4 602.5 617.5 576.4 590.5 618.4 631.5 602.5 N11N16 576.4 618.4 602.4 616.5 631.5 590.4 604.5 632.4 645.5 616.5 N11N18 604.4 646.4 630.4 644.5 659.5 618.4 632.5 660.4 673.5 644.5 N11.sup.2N12 688.5 730.5 714.5 728.6 743.6 702.5 716.6 744.5 757.6 728.6 N12N12 534.4 576.4 560.4 574.5 589.5 548.4 562.5 590.4 603.5 574.5 N12N13 548.4 590.4 574.4 588.5 603.5 562.4 576.5 604.4 617.8 588.5 N12N15 576.4 618.4 602.4 616.5 631.5 590.4 604.5 632.8 645.5 616.5 N12N16 590.4 632.4 616.4 630.5 645.5 604.4 618.8 646.4 659.5 630.8 N12N18 618.4 660.4 644.4 658.5 673.5 632.4 646.5 674.4 687.5 658.5 N12.sup.2N12 702.5 744.5 728.8 742.6 757.6 716.5 730.8 758.5 771.6 742.6 N13N13 562.4 604.4 588.4 602.8 617.5 576.4 590.5 618.4 631.5 602.5 N13N15 590.4 632.4 616.4 630.5 645.5 604.4 618.5 646.4 659.5 630.5 N13N16 604.4 646.4 630.4 644.5 659.8 618.4 632.5 660.4 673.5 644.5 N13N18 632.4 674.4 658.4 672.5 687.5 646.4 660.5 688.4 701.5 672.5 N13.sup.2N12 716.5 758.5 742.5 756.6 771.6 730.6 744.6 772.5 785.6 756.6 N15N15 618.4 660.4 644.4 658.5 673.5 632.4 646.5 674.4 687.5 658.5 N15N16 632.4 674.4 658.4 672.5 687.9 646.4 660.5 688.4 701.5 672.5 N15N18 660.4 702.4 686.4 700.5 715.5 674.4 688.5 716.4 729.5 700.5 N15.sup.2N12 744.5 786.5 770.5 784.6 799.6 758.5 772.6 800.5 813.6 784.6 N16N16 646.9 688.4 672.4 686.9 701.5 660.4 674.5 702.4 715.5 686.5 N16N18 674.4 716.9 700.4 714.7 729.5 688.4 702.5 730.4 743.5 714.5 N16.sup.2N12 758.5 800.5 784.5 798.6 813.6 772.5 786.6 814.5 827.6 798.6 N18N18 702.9 744.4 728.4 742.5 757.5 716.8 730.5 758.4 771.5 742.5 N18.sup.2N12 786.5 828.5 812.5 826.6 841.6 800.5 814.6 842.5 855.6 826.6 .sup.2N12.sup.2N12 870.6 912.6 896.9 910.7 926.1 884.6 898.9 926.6 939.7 911.2

Example 1.1: Parallel Synthesis and Characterization of the Library of Amino Lipid Compounds of S8NxDy Series

[0200] ##STR00052##

wherein n3, -NRR, R.sup.1 and R.sup.2 are as defined above.

##STR00053##

[0201] Cyanuric chloride (2 mmol) and THF (10 mL) were added to a 50 mL dry reaction bottle, and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-octanethiol (2 mmol) and DIPEA (2.4 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. The reaction solution was transferred to a 15 mL centrifuge tube, fixed to a volume of 15 mL, and then centrifuged in a centrifuge (2000 r/min, 1 min). Step I reaction solution (15 mL, 0.13 M) was then obtained.

[0202] The Step I reaction solution was transferred to 11 1.5 mL reaction bottles (each 1.15 mL, 0.15 mmol) with a pipette, and a linear alkylamine (0.15 mmol) and a solution of DIPEA in THF (0.35 mL, 0.5 M) were added to the corresponding reaction bottle, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material.

[0203] Each Step II reaction solution was transferred to 10 1.5 mL EP tubes (each 0.1 mL, 0.01 mmol) with a pipette, and a solution of a diamine in THF (0.12 mL, 0.012 mmol, 0.1M) and a solution of DIPEA in THF (0.02 mL, 0.1M) were added to the corresponding EP tube, followed by reaction for 1 h in a heated shaking reactor (Thermo-Shaker) at 78° C. TLC detection showed no Step II raw material. After the reaction was complete, the solvent in the reaction tube was evaporated to dryness at normal temperature to obtain 110 amino lipid compounds S8NxDy. 10 representative compounds among them were selected for measurement by mass spectrometry. The results are shown in Table 1 below.

TABLE-US-00005 TABLE 1 MW/z values of representative compounds Compound Molecular Molecular Found No. Structural formula formula weight (M + H).sup.+  1 S8N11D1 [00054] C26H52N6S 480.4 481.5  2 S8N11D2 [00055] C28H54N6OS 522.4 523.4  3 S8N11D3 [00056] C28H54N6S 506.4 507.6  4 S8N11D4 [00057] C29H56N6S 520.4 521.7  5 S8N11D5 [00058] C29H57N7S 535.4 536.5  6 S8N11D6 [00059] C27H54N6S 494.4 495.6  7 S8N11D7 [00060] C28H56N6S 508.4 509.6  8 S8N11D8 [00061] C29H56N6OS 536.4 537.7  9 S8N11D9 [00062] C30H59N7S 549.5 550.6 10 S8N11D10 [00063] C29H56N6S 520.4 521.6

Example 1.1.1: One-Pot Synthesis and Characterization of Representative Amino Lipid Compound S8N11D6

[0204] ##STR00064##

[0205] Cyanuric chloride (1 mmol) and THF (10 mL) were added to a 20 mL dry reaction tube and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-octanethiol (1 mmol) and DIPEA (1.2 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. After the reaction solution was warmed to room temperature, undecylamine (1 mmol) and DIPEA (1.2 mol) were added, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material. N,N-dimethylpropanediamine (1.2 mmol) and DIPEA (2 mol) were then added, warmed to 78° C. under stirring and reacted for 1 h. TLC detection showed no Step II raw material. Purification by an automatic purification system (forward silica column, eluting with a gradient of 0 to 10% DCM:MeOH) to obtain 440.4 mg of a white solid, with a yield of 89% for the reactions of three steps, and a purity of >99%. .sup.1H NMR (400 MHz, CDCl.sub.3) δ 3.54 (m, 2H), 3.34 (m, 2H), 3.01 (m, 4H), 2.80-2.73 (m, 6H), 2.07 (m, 2H), 1.67 (m, 2H), 1.53 (m, 2H), 1.38 (m, 2H), 1.28 (m, 2H), 1.24 (m, 24H), 0.88-0.84 (m, 6H). ESI-MS calculated for C27H55N6S+[M+H]+ 495.4, found 495.6.

Example 1.2: Parallel Synthesis and Characterization of the Library of Amino Lipid Compound of S6SxDy Series

[0206] ##STR00065##

[0207] wherein n3, —NRR, R.sup.1 and R.sup.2 are as defined above.

##STR00066##

[0208] Cyanuric chloride (2 mmol) and THF (10 mL) were added to a 50 mL dry reaction bottle and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-hexanethiol (2 mmol) and DIPEA (2.4 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. The reaction solution was transferred to a 15 mL centrifuge tube, fixed to a volume of 15 mL, and then centrifuged in a centrifuge (2000 r/min, 1 min). Step I reaction solution (15 mL, 0.13 M) was then obtained.

[0209] The Step I reaction solution was transferred to 11 1.5 mL reaction bottles (each 1.15 mL, 0.15 mmol) with a pipette, and a linear alkylthiol (0.15 mmol) and a solution of DIPEA in THF (0.35 mL, 0.5 M) were added to the corresponding reaction bottle, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material.

[0210] Each Step II reaction solution was transferred to 10 1.5 mL EP tubes (each 0.1 mL, 0.01 mmol) with a pipette, then a solution of a diamine in THF (0.12 mL, 0.012 mmol, 0.1M) and a solution of DIPEA in THF (0.02 mL, 0.1M) were added to the corresponding EP tube, followed by reaction for 1 h in a heated shaking reactor (Thermo-Shaker) at 78° C. TLC detection showed no Step II raw material. After the reaction was complete, the solvent in the reaction tube was evaporated to dryness at normal temperature to obtain 110 amino lipid compounds S6SxDy. 10 representative compounds among them were selected for measurement by mass spectrometry. The results are shown in Table 2 below.

TABLE-US-00006 TABLE 2 MW/z values of representative compounds Compound Molecular Molecular Found No. Structural formula formula weight (M + H).sup.+  1 S6S11D1 [00067] C24H47N5S2 469.3 470.3  2 S6S11D2 [00068] C26H49N5OS2 511.3 512.3  3 S6S11D3 [00069] C26H49N5S2 495.3 496.3  4 S6S11D4 [00070] C27H51N5S2 520.4 521.4  5 S6S11D5 [00071] C27H52N6S2 524.4 525.4  6 S6S11D6 [00072] C25H49N5S2 483.3 484.3  7 S6S11D7 [00073] C26H51N5S2 497.4 498.5  8 S6S11D8 [00074] C27H51N5OS2 525.4 526.5  9 S6S11D9 [00075] C28H54N6S2 538.4 539.4 10 S6S11D10 [00076] C27H51N5S2 509.4 510.4

Example 1.2.1: One-Pot Synthesis and Characterization of Representative Amino Lipid Compound S6S11D6

[0211] ##STR00077##

[0212] Cyanuric chloride (1 mmol) and THF (10 mL) were added to a 20 mL dry reaction bottle and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-hexanethiol (1 mmol) and DIPEA (1.2 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. After the reaction solution was warmed to room temperature, undecylthiol (1 mmol) and DIPEA (1.2 mol) were added, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material. N,N-dimethylpropanediamine (1.2 mmol) and DIPEA (2 mol) were then added, warmed to 78° C. with stirring and reacted for 1 h. TLC detection showed no Step 11 raw material. Purification by an automatic purification system (forward silica column, eluting with a gradient of 0 to 10% DCM:MeOH) to obtain 445.1 mg of a white solid with a yield of 92% of the reactions of three steps and a purity of 99%. .sup.1H NMR (400 MHz, CDCl.sub.3) δ 3.51 (m, 2H), 3.04-3.01 (m, 4H), 2.81-2.74 (m, 6H), 2.09 (m, 2H), 1.68 (m, 2H), 1.55 (m, 2H), 1.33 (m, 2H), 1.29 (m, 2H), 1.23 (m, 22H), 0.88-0.84 (m, 6H). ESI-MS calculated for C.sub.25H.sub.50N.sub.5S.sub.2.sup.+ [M+H].sup.+ 484.4, found 484.4.

Example 1.3: Parallel Synthesis and Characterization of the Library of Amino Lipid Compounds of N6NxDy Series

[0213] ##STR00078##

[0214] wherein n3, —NRR, R.sup.1 and R.sup.2 are as defined above.

##STR00079##

[0215] Cyanuric chloride (2 mmol) and THF (10 mL) were added to a 50 mL dry reaction tube and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-hexylamine (2 mmol) and DIPEA (2.4 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. The reaction solution was transferred to a 15 mL centrifuge tube, fixed to a volume of 15 mL, and then centrifuged in a centrifuge (2000 r/min, 1 min). Step I reaction solution (15 mL, 0.13 M) was then obtained.

[0216] The Step I reaction solution was transferred to 11 1.5 mL reaction bottles (each 1.15 mL, 0.15 mmol) with a pipette, and a linear alkylamine (0.15 mmol) and a solution of DIPEA in THF (0.35 mL, 0.5 M) were added to the corresponding reaction bottle, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material.

[0217] Each Step II reaction solution was transferred to 10 1.5 mL EP tubes (each 0.1 mL, 0.01 mmol) with a pipette, and a solution of a diamine in THF (0.12 mL, 0.012 mmol, 0.1M) and a solution of DIPEA in THF (0.02 mL, 0.1M) were added to the corresponding EP tube, followed by reaction for 1 h in a heated shaking reactor (Thermo-Shaker) at 78° C. TLC detection showed no Step II raw material. After the reaction was complete, the solvent in the reaction tube was evaporated to dryness at normal temperature to obtain 110 amino lipid compounds N6NxDy. 10 representative compounds among them were selected for measurement by mass spectrometry. The results are shown in Table 3.

TABLE-US-00007 TABLE 3 MW/z values of representative compounds Compound Molecular Molecular Found No. Structural formula formula weight (M + H).sup.+  1 N6N11D1 [00080] C24H49N7 435.4 436.4  2 N6N11D2 [00081] C26H51N7O 477.4 478.4  3 N6N11D3 [00082] C26H51N7 461.4 462.4  4 N6N11D4 [00083] C27H53N7 475.4 476.4  5 N6N11D5 [00084] C27H54N8 490.4 491.4  6 N6N11D6 [00085] C25H51N7 449.4 450.4  7 N6N11D7 [00086] C26H53N7 463.4 464.4  8 N6N11D8 [00087] C27H53N7O 491.4 492.4  9 N6N11D9 [00088] C22H45N9 435.4 436.4 10 N6N11D10 [00089] C27H53N7 475.4 476.4

Example 1.3.1: One-Pot Synthesis and Characterization of Representative Amino Lipid Compound N6N11D6

[0218] ##STR00090##

[0219] Cyanuric chloride (1 mmol) and THF (10 mL) were added to a 20 mL dry reaction tube and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-hexylamine (1 mmol) and DIPEA (1.2 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. After the reaction solution was warmed to room temperature, undecylamine (1 mmol) and DIPEA (1.2 mol) were added, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material. N,N-dimethylpropanediamine (1.2 mmol) and DIPEA (2 mol) were then added, warmed to 78° C. with stirring and reacted for 1 h. TLC detection showed no Step II raw material. Purification by an automatic purification system (forward silica column, eluting with a gradient of 0 to 10% DCM:MeOH) to obtain 395.7 mg of a white solid, with a yield of 88% for the reactions of three steps and a purity of 99%. .sup.1H NMR (400 MHz, CDCl.sub.3) δ 3.54 (m, 2H), 3.05-3.02 (m, 4H), 2.82-2.73 (m, 6H), 2.08 (m, 2H), 1.69 (m, 2H), 1.54 (m, 2H), 1.34 (m, 2H), 1.30 (m, 2H), 1.24 (m, 22H), 0.89-0.85 (m, 6H). ESI-MS calculated for C.sub.25H.sub.52N.sub.7.sup.+ [M+H].sup.+ 450.4, found 450.4.

Example 1.4: Parallel Synthesis and Characterization of the Library of Amino Lipid Compounds of S6SxOy Series

[0220] ##STR00091##

[0221] wherein n4=1, 2, 3 or 4; —NR′R′ represents a dialkylamino or cyclic amino moiety in O1 to O10 described above; and R.sup.1 and R.sup.2 are as defined above.

##STR00092##

[0222] Cyanuric chloride (2 mmol) and THF (10 mL) were added to a 50 mL dry reaction bottle and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-hexanethiol (2 mmol) and DIPEA (2.4 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. The reaction solution was transferred to a 15 mL centrifuge tube, fixed to a volume of 15 mL and then centrifuged in a centrifuge (2000 r/min, 1 min). Step I reaction solution (15 mL, 0.13 M) was then obtained.

[0223] The Step I reaction solution was transferred to 11 1.5 mL reaction bottles (each 1.15 mL, 0.15 mmol) with a pipette, and a linear hydrocarbylthiol (0.15 mmol) and a solution of DIPEA in THF (0.35 mL, 0.5 M) were added to the corresponding reaction bottle, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material

[0224] Each Step II reaction solution was transferred to 10 1.5 mL EP tubes (each 0.1 mL, 0.01 mmol) with a pipette, and a solution of a hydroxylamine in THF (0.12 mL, 0.012 mmol, 0.1M) and a solution of DIPEA in THF (0.02 mL, 0.1M) were added to the corresponding EP tube, followed reaction for 2 h in a shaking reactor (Thermo-Shaker) at room temperature. TLC detection showed no Step II raw material. After the reaction was complete, the solvent in the reaction tube was evaporated to dryness at normal temperature to obtain 110 amino lipid compounds S6SxOy. 10 representative compounds among them were selected for measurement by mass spectrometry. The results are shown in Table 1.4 below.

TABLE-US-00008 TABLE 1.4 MW/z values of representative compounds Compound Molecular Molecular Found No. Structural formula formula weight (M + H).sup.+  1 S19S9O1 [00093] C34H64N4OS2 608.5 609.8  2 S19S9O2 [00094] C35H66N4OS2 622.5 623.7  3 S19S9O3 [00095] C36H68N4OS2 636.5 637.9  4 S19S9O4 [00096] C37H69N5OS2 663.5 664.7  5 S19S9O5 [00097] C38H71N5OS2 677.5 678.9  6 S19S9O6 [00098] C36H66N4O2S2 650.5 651.8  7 S19S9O7 [00099] C37H68N4O2S2 664.5 665.8  8 S19S9O8 [00100] C36H66N4OS2 634.5 635.7  9 S19S9O9 [00101] C37H68N4OS2 648.5 649.8 10 S19S9O10 [00102] C37H68N4OS2 648.5 649.7

Example 1.4.1: One-Pot Synthesis and Characterization of Representative Amino Lipid Compound S19S9O8

[0225] ##STR00103##

[0226] Cyanuric chloride (1 mmol) and THF (10 mL) were added to a 20 mL dry reaction bottle and cooled to −20° C. under stirring in a cold bath, followed by successive addition of 1-oleylthiol (1 mmol) and DIPEA (1.2 mmol), and a large amount of precipitate immediately occurred in the reaction solution. TLC detection was performed after reaction for 5 min, the reaction was complete. After the reaction solution was warmed to room temperature, 1-nonylthiol (1 mmol) and DIPEA (1.2 mol) were added, and reacted for 2 h under stirring at room temperature. TLC detection showed no Step I raw material. N-(2-hydroxyethyl)-pyrrolidine (1.2 mmol) and DIPEA (2 mol) were then added, and reacted for 2 h at room temperature. TLC detection showed no Step II raw material. Purification by an automatic purification system (forward silica column, eluting with a gradient of 0 to 10% DCM:MeOH) to obtain 546.2 mg of a white solid, with a yield of 86% for the reactions of three steps and a the purity of 99%. .sup.1H NMR (400 MHz, CDCl.sub.3) δ 5.35 (m, 2H), 4.21 (m, 2H), 3.51 (m, 4H), 2.67-2.54 (m, 6H), 2.19 (m, 4H), 1.68 (m, 4H), 1.55-1.23 (m, 38H), 0.88-0.84 (m, 6H). ESI-MS calculated for C.sub.36H.sub.67N.sub.4OS.sub.2.sup.+ [M+H].sup.+ 635.5, found 635.7.

Example 2: Evaluation on the Performances of Lipid Nanoparticles Prepared from Amino Lipid Compounds in In Vivo Delivery of Luciferase mRNA

[0227] 1. Preparation of Lipid Nanoparticles

[0228] Formulation Method 1:

[0229] The amino lipid compound of the invention was mixed with DOPE, cholesterol and PEG2000-DMG in a molar ratio of 45:10:42.5:2.5, and dissolved in absolute ethanol such that the molar concentration of the amino lipid compound was 0.001-0.01 mmol/L. By using a microinjection pump, the resultant ethanol solution and a sodium acetate solution (50 mM, pH=4.0) in which luciferase mRNA (Fluc mRNA, TriLink) was dissolved were mixed in a volume ratio of 1:3 in a microchannel chip to prepare a crude solution of lipid nanoparticles, which was then dialyzed in 1×PBS at a controlled temperature of 4° C. for 6 h using a dialysis box (Fisher, MWCO 20,000) and filtered through a 0.22 μm microporous filter membrane before use. The mass ratio of the amino lipid compound to Fluc mRNA was about 10:1. The resultant solution of lipid nanoparticles (LNPs) was administered to the tested animals by subcutaneous administration.

[0230] Characterization of the Lipid Nanoparticles:

[0231] Characterization of particle size: the particle size and PDI of the prepared lipid nanoparticles were determined by Nano-ZSZEN3600 (Malvern). 40 uL of LNP solution was taken for particle size measurement with circulation for three times, 30 s for each circulation.

[0232] Detection of encapsulation rate: the concentration of LNP RNA was detected by Qubit® RNA HS Assay kit. The theoretical RNA concentration was given by the total amount of RNA input divided by the total volume of the final solution.

[00001]$\mathrm{Encapsulation}\mathrm{rate}=\frac{\mathrm{Theoretical}\mathrm{RNA}\mathrm{concentration}-\mathrm{Free}\mathrm{RNA}\mathrm{concentration}}{\mathrm{Theoretical}\mathrm{RNA}\mathrm{concentration}}\times 100\%$

TABLE-US-00009 TABLE 4 Characterization data of LNPs prepared from representative amino lipid compounds using Formulation Method 1. Amino Particle Encapsulation lipid No. Structure size (nm) PDI rate  1 S16N9D3 [00104] 87 ± 4 0.08 98.9%  2 S15N11D5 [00105] 79 ± 5 0.02 99.2%  3 S12N13D6 [00106] 89 ± 5 0.05 99.0%  4 S16N7D9 [00107] 102 ± 5  0.01 98.6%  5 S16N8D10 [00108] 90 ± 5 0.04 97.2%  6 S7S18D3 [00109] 121 ± 5  0.10 99.5%  7 S9S16D5 [00110] 152 ± 5  0.04 99.1%  8 S11S12D8 [00111] 80 ± 5 0.02 98.3%  9 S8S16D9 [00112] 96 ± 5 0.01 98.7% 10 S10S16D10 [00113] 136 ± 5  0.03 99.5% 11 S19S9O8 [00114] 88 ± 5 0.02 99.6% 12 S19S9O9 [00115] 110 ± 5  0.04 99.2%

[0233] Formulation Method 2:

[0234] The preparation method was the same as Formulation method 1, except that amino lipid compound, DSPC, cholesterol and PEG2000-DMG were used in a molar ratio of 50:10:38.5: 1.5. The resultant solution of lipid nanoparticles (LNPs) was administered to the tested animals by tail vein and intramuscular injection.

TABLE-US-00010 TABLE 5 Characterization data of LNPs prepared from representative amino lipid compounds using Formulation method 2. Amino lipid No. Particle size (nm) PDI Encapsulation rate 1 S16N9D3 127 ± 5  0.06 99.1% 2 S15N11D5 95 ± 5 0.01 98.8% 3 S12N13D6 96 ± 5 0.04 99.2% 4 S16N7D9 92 ± 5 0.05 99.2% 5 S16N8D10 120 ± 5  0.03 98.6% 6 S7S18D3 95 ± 5 0.04 99.3% 7 S9S16D5 130 ± 5  0.05 99.6% 8 S11S12D8 90 ± 5 0.01 98.9% 9 S8S16D9 115 ± 5  0.02 99.4% 10 S10S16D10 125 ± 5  0.04 99.2% 11 S19S9O8 88 ± 5 0.03 99.2% 12 S19S9O9 110 ± 5  0.05 99.0%

[0235] 2. Animal Tests

[0236] Animal Preparation: 6-week aged female BALB/c mice weighed about 20 g were selected and fed in a SPF-grade feeding room. Animal tests were conducted strictly according to the guidelines of national health institutions and the requirements of animal ethics.

[0237] In vivo delivery: 9 mice were assigned randomly to each group, and the lipid nanoparticle solution was injected by three routes of administration, i.e., subcutaneous, intramuscular and tail vein injection at a dosage of 0.5 mg/kg Fluc mRNA (3 mice for each route of administration). After 12 hours, 200 μL of 10 mg/mL potassium salt of D-fluorescein (PerkinElmer) was injected into each mouse through the tail vein. After 10 min, the mice were placed under an in vivo imaging system (IVIS-200, Xenogen) to observe the total fluorescence intensity of each mouse and take photographs for record. The expression intensity of Fluc mRNA delivered by representative amino lipid compounds through the three routes of administration are shown in Table 5-7. DLin-MC3 was used as control.

TABLE-US-00011 TABLE 5 Expression intensity of Fluc mRNA delivered by subcutaneous administration of representative amino lipid compounds. Amino lipid No. Fluorescence intensity S16N9D3 2.7E+07 S15N11D5 1.9E+08 S12N13D6 8.6E+06 S16N7D9 1.4E+07 CD10 3.7E+08 S7S18D3 2.9E+08 S9S16D5 4.2E+07 S11S12D8 1.1E+07 S8S16D9 4.2E+06 S10S16D10 4.7E+07 S19S9O8 1.1E+07 S19S9O9 2.8E+07 DLin-MC3 (control) 3.1E+06

TABLE-US-00012 TABLE 6 Expression intensity of Fluc mRNA delivered by intramuscular administration of representative amino lipid compounds. No. Fluorescence intensity S16N9D3 4.3E+06 S15N11D5 3.7E+06 S12N13D6 1.2E+06 S16N7D9 4.3E+07 S16N8D10 3.9E+06 S7S18D3 8.7E+07 S9S16D5 5.2E+06 S11S12D8 4.7E+06 S8S16D9 8.2E+06 S10S16D10 3.2E+06 S19S9O8 9.1E+07 S19S9O9 1.8E+07 DLin-MC3 (control) 2.7E+07

TABLE-US-00013 TABLE 7 Expression intensity of Fluc mRNA delivered by tail vein administration of representative amino lipid compounds. No. Fluorescence intensity S16N9D3 5.3E+06 S15N11D5 3.7E+06 S12N13D6 3.9E+06 S16N7D9 5.1E+07 S16N8D10 3.2E+06 S7S18D3 8.1E+07 S9S16D5 7.5E+06 S11S12D8 3.8E+06 S8S16D9 6.5E+06 S10S16D10 2.9E+06 S19S9O8 1.1E+08 S19S9O9 3.1E+07 DLin-MC3 (control) 2.7E+07

Example 3: Evaluation on the Performances of Lipid-Nanoparticles Prepared from Amino Lipid Compounds in In Vivo Delivery of Ovalbumin mRNA and Immunity

[0238] Formulation Method:

[0239] The amino lipid compound of the invention was mixed with DOPE, cholesterol and PEG2000-DMG in a molar ratio of 50:10:38.5:1.5 and dissolved in absolute ethanol such that the molar concentration of the amino lipid compound was 0.001-0.01 mmol/L. Ovalbumin mRNA (OVA mRNA, TriLink) was dissolved in sodium acetate solution (50 mM, pH=4.0). By using a microinjection pump, the resultant ethanol solution and sodium acetate solution (50 mM, pH=4.0) were mixed in a volume ratio of 1:3 in a microchannel chip to prepare a crude solution of lipid nanoparticles, which was then dialyzed in 1×PBS at a controlled temperature of 4° C. for 6 h using a dialysis box (Fisher, MWCO 20,000), and filtered through a 0.22 μm microporous filter membrane before use. The mass ratio of the amino lipid compound to ovalbumin mRNA (OVA mRNA) was about 10:1.

[0240] Animal Preparation: 6-week aged female BALB/c mice weighed about 20 g were selected and fed in a SPF-grade feeding room. Animal tests were conducted strictly according to the guidelines of national health institutions and the requirements of animal ethics.

[0241] In vivo delivery: 3 mice were assigned randomly to each group, and the lipid nanoparticle solution was intramuscularly injected into the leg at a dosage of 0.5 mg/kg mRNA (Day 0). After 7 days, one booster injection was performed at the same dosage (Day 7). On Day 21, blood was taken from the tail vein for serological analysis. DLin-MC3 was used as control (FIG. 1).

[0242] Enzyme-linked immunosorbent assay (ELISA): a flat-bottomed 96-well plate (Nunc) was pre-coated, with a concentration of OVA protein of 0.5 μg protein per well in 50 mM carbonate buffer (pH 9.6), and was allowed to stay overnight at 4° C. and then blocked with 5% glycine. Serum obtained from animals receiving the lipid nanoparticle solution containing the mRNA was diluted from 10.sup.2 to 10.sup.6 times with PBS-0.05% Tween (PBS-T) at pH 7.4, and added to the wells, incubated at room temperature and placed at 37° C. for 1 h. Horseradish peroxidase (HRP, Invitrogen) coupled goat anti-mouse IgG was used for labeling in PBS-T-1% BSA at a dilution rate of 1:10,000. After addition of the HRP substrate, the absorbance at 450 nm was measured in ELISA microplate reader (Bio-Rad). As shown in FIG. 1, the IgG antibody titers for S7S18D3, S16N7D9, S19S9O8 and S19S9O9 were significantly superior to that of the control.

Example 4: Preliminary Screening of Amino Lipid Compounds as DNA Vectors

[0243] Cell line: HEK293 cells (ATCC CRL-1573™)

[0244] Medium: DMEM supplemented with 10% fetal bovine serum (Invitrogen)

[0245] Mode of screening: cell transfection on 96-well plates

[0246] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was measured using nucleus dye Hoechst—see FIG. 2). Lipofectamine2000 (Invitrogen) was used as positive control, according to the manufacturer's instructions.

[0247] Method: an 8-channel pipette was used for sample addition. The contents shown were for a single well of a 96-well flat plate.

[0248] 1. The compound (0.01 mmol) prepared in Example 1 was dissolved in 1 mL of anhydrous ethanol. After ultrasonically dissolved, 10 μL of the resultant amino lipid solution in ethanol was taken and mixed with 5 μL of DOPE solution in ethanol (0.01 m), and then to the obtained mixture was added 35 μL of 0.2M sodium acetate buffer (pH 5.6), and 50 μL of liposome solution was prepared by vortex at a constant rotating speed for 30 s. 4 μL was taken from the 50 μL liposome solution and added to 46 μL of 0.02M sodium acetate buffer (pH 5.6), and the final liposome solution was formed by vortex at a constant rotating speed for 30 s. 5 μL was taken from the final liposome solution and mixed with 75 ng plasmid DNA (psin-EGFP-IRES-Puro, Clontech) dissolved in 5 μL of 0.02 M sodium acetate buffer, and was allowed to stay at room temperature for 30 min to form a lipid/DNA transfection complex.

[0249] 2. 10 μL of the lipid/DNA transfection complex was incubated at room temperature for 30 min, followed by addition of 90 μL of fresh resuspended cells (3-5×10.sup.4 cells) and mixing with a pipette. 100 μL of cells+lipid/DNA complex was transferred to separate wells of a 96-well culture plate immediately, and placed in an incubator containing 5% CO.sub.2 at 37° C.

[0250] 3. Hoechst33258 (Invitrogen) was added at a final concentration of 0.2 μg/mL to the cells 20 to 24 hours after initial cell transfection, and cultured in darkness at 37° C. for 15 min. Afterwards, the cells were washed once with a PBS solution, and then added with medium for culture for 20 to 24 h.

[0251] 4. The cells were placed in a high-throughput confocal microscope (Molecular Devices ImageXpress), and four visual fields of the image of the cells were captured for each well, and images at three laser wavelengths were captured for each sample: bright field images of cells (FIG. 2(a) and FIG. 2(b)), Hoechst-staining images showing total nuclei (FIG. 2(c) and FIG. 2(d)) and GFP images showing success in transfection with the plasmid DNA and the expression of GFP (FIG. 2(e) and FIG. 2(f)). MetaXpress software was used to separately count the cells in the Hoechst-staining images and GFP images, and then the number of cells expressing GFP was divided by the total number of nuclei to give the absolute cell transfection efficiency. The absolute transfection efficiency was calculated as follows:

[00002]$\mathrm{Absolute}\mathrm{transfection}\mathrm{efficiency}\left(\%\right)=\frac{\mathrm{Number}\mathrm{of}\mathrm{cells}\mathrm{expressing}\mathrm{GFP}}{\mathrm{Number}\mathrm{of}\mathrm{Hoechst}-\mathrm{strained}\mathrm{cells}}$

[0252] Results: The DNA transfection efficiency in HEK293 cells for 2530 compounds is shown in Table 8.

TABLE-US-00014 TABLE 8 Absolute DNA transfection efficiency in HEK293 cells for 2530 compounds. D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 S6N6 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% S6N7 0.1% 0.0% 0.0% 1.1% 3.7% 0.4% 0.1% 0.0% 0.2% 2.9% S6N8 0.2% 0.3% 2.0% 1.7% 3.4% 0.6% 0.9% 0.0% 1.2% 0.4% S6N9 0.1% 0.2% 0.4% 0.4% 7.9% 1.5% 1.1% 0.0% 0.8% 4.3% S6N11 1.5% 0.2% 2.8% 3.3% 17.5% 1.9% 2.2% 1.5% 21.1% 7.9% S6N12 4.7% 0.9% 6.2% 2.0% 25.9% 6.0% 2.2% 4.0% 38.8% 21.3% S6N13 6.5% 1.9% 9.9% 2.1% 24.1% 12.9% 2.0% 4.9% 38.3% 51.6% S6N15 5.8% 2.0% 15.9% 1.7% 22.3% 25.9% 1.2% 3.3% 28.4% 31.1% S6N16 6.6% 1.4% 19.8% 2.4% 19.6% 22.8% 2.6% 4.2% 20.6% 19.7% S6N18 21.0% 2.5% 21.9% 3.5% 15.4% 21.8% 5.2% 8.1% 14.1% 13.0% S6.sup.2N12 0.4% 0.0% 0.1% 0.1% 0.0% 0.2% 0.3% 0.0% 0.4% 0.0% S7N6 17.6% 1.8% 34.7% 8.7% 28.5% 27.2% 11.2% 4.7% 20.3% 6.3% S7N7 23.6% 2.5% 9.2% 11.3% 33.5% 33.5% 11.4% 5.3% 10.9% 8.6% S7N8 15.6% 2.7% 9.3% 15.5% 22.1% 22.3% 26.8% 2.7% 14.9% 9.5% S7N9 28.8% 13.9% 12.3% 13.0% 22.0% 25.9% 33.2% 4.6% 22.8% 15.0% S7N11 20.3% 31.1% 25.3% 6.9% 43.7% 42.1% 9.6% 13.9% 43.9% 45.9% S7N12 18.2% 25.6% 17.4% 9.7% 35.1% 54.6% 5.5% 17.7% 46.4% 45.7% S7N13 11.7% 22.1% 17.9% 6.4% 23.3% 43.2% 3.1% 17.3% 36.9% 54.2% S7N15 19.5% 14.1% 31.4% 4.9% 20.4% 15.9% 7.2% 7.9% 17.6% 30.9% S7N16 20.0% 12.9% 21.2% 2.9% 18.2% 26.2% 6.4% 8.1% 12.9% 15.8% S7N18 10.6% 16.6% 16.1% 3.2% 8.2% 18.4% 3.9% 5.9% 4.2% 16.3% S7.sup.2N12 0.2% 0.0% 0.1% 0.0% 0.2% 0.6% 0.2% 0.0% 0.3% 0.5% S8N6 3.4% 0.2% 3.2% 2.6% 5.0% 4.3% 1.8% 0.0% 2.2% 0.5% S8N7 3.0% 0.4% 3.9% 3.8% 3.6% 8.5% 1.4% 0.8% 3.6% 1.2% S8N8 9.3% 1.5% 8.5% 2.9% 9.1% 8.7% 5.2% 2.9% 7.4% 6.1% S8N9 33.6% 10.7% 32.7% 15.5% 35.9% 33.3% 26.0% 14.8% 32.1% 36.3% S8N11 42.2% 25.4% 52.0% 14.3% 52.7% 99.4% 24.6% 13.7% 63.6% 46.3% S8N12 22.1% 38.1% 17.8% 7.6% 41.7% 78.3% 9.5% 16.1% 48.3% 44.5% S8N13 18.3% 19.7% 30.5% 3.8% 28.3% 55.1% 8.9% 13.3% 27.9% 18.7% S8N15 8.0% 4.9% 9.9% 0.9% 10.4% 23.7% 2.2% 7.7% 12.4% 22.6% S8N16 7.1% 2.9% 3.3% 1.0% 14.3% 3.7% 5.2% 8.2% 9.7% 13.4% S8N18 4.8% 2.6% 6.7% 0.9% 8.6% 20.6% 4.1% 5.1% 5.3% 9.6% S8.sup.2N12 0.0% 0.0% 0.1% 0.0% 0.8% 0.5% 0.1% 0.0% 0.7% 0.8% S9N6 16.1% 2.1% 27.0% 20.7% 22.4% 8.8% 9.8% 7.8% 11.0% 9.7% S9N7 36.0% 4.4% 27.3% 21.9% 18.3% 12.4% 15.2% 6.1% 12.1% 9.3% S9N8 37.3% 13.9% 37.6% 27.3% 30.3% 17.9% 15.7% 12.2% 25.7% 17.2% S9N9 35.3% 24.0% 54.9% 18.0% 47.4% 60.6% 49.8% 14.8% 50.7% 34.5% S9N11 35.3% 16.2% 43.4% 8.3% 45.0% 55.4% 15.7% 26.8% 49.3% 42.5% S9N12 39.3% 13.0% 47.3% 8.0% 48.2% 70.5% 12.4% 13.6% 28.8% 25.8% S9N13 25.0% 11.1% 31.6% 6.7% 27.9% 31.8% 6.5% 11.3% 19.9% 29.4% S9N15 29.8% 7.3% 22.7% 4.2% 16.1% 13.4% 4.6% 5.3% 10.9% 19.0% S9N16 19.2% 23.5% 31.3% 8.1% 21.7% 29.7% 6.4% 18.4% 20.3% 21.8% S9N18 24.2% 10.2% 33.8% 9.0% 22.9% 47.5% 6.0% 26.1% 15.8% 11.2% S9.sup.2N12 0.3% 0.0% 0.0% 0.0% 0.3% 1.1% 0.2% 0.0% 0.6% 1.1% S10N6 6.9% 0.5% 7.3% 5.7% 7.0% 3.5% 6.6% 0.6% 5.5% 0.9% S10N7 8.2% 2.4% 7.4% 3.6% 7.5% 6.2% 8.1% 2.6% 4.5% 1.1% S10N8 7.1% 3.7% 3.9% 2.1% 13.2% 10.7% 2.0% 3.4% 5.6% 0.6% S10N9 7.1% 3.7% 4.9% 2.7% 11.9% 21.0% 6.9% 3.4% 12.0% 4.5% S10N11 4.8% 1.5% 12.6% 8.7% 7.2% 26.5% 5.0% 3.8% 10.8% 5.4% S10N12 1.8% 3.7% 7.2% 4.7% 2.6% 19.8% 5.9% 5.3% 3.6% 6.8% S10N13 6.1% 4.2% 7.7% 4.2% 2.1% 7.9% 4.4% 5.7% 0.4% 3.2% S10N15 4.8% 1.4% 11.5% 4.1% 3.2% 9.1% 1.7% 5.1% 4.1% 6.9% S10N16 7.8% 1.2% 8.8% 4.4% 3.1% 13.6% 4.8% 3.0% 5.0% 8.7% S10N18 9.0% 2.1% 11.9% 4.9% 1.8% 7.8% 4.0% 0.3% 3.3% 3.8% S10.sup.2N12 3.2% 0.0% 1.1% 0.1% 0.9% 4.3% 0.7% 0.0% 0.5% 3.3% S11N6 33.1% 19.0% 8.3% 29.0% 21.6% 29.3% 25.0% 13.3% 13.5% 8.8% S11N7 27.6% 11.7% 19.4% 4.6% 22.8% 34.0% 11.6% 13.4% 16.1% 28.5% S11N8 19.8% 18.6% 26.0% 5.9% 19.3% 36.9% 10.1% 12.2% 23.6% 33.4% S11N9 12.1% 13.6% 23.1% 1.1% 20.5% 40.1% 2.0% 8.6% 22.4% 32.5% S11N11 17.8% 6.3% 23.4% 1.0% 10.1% 22.8% 6.8% 2.5% 4.9% 5.6% S11N12 16.2% 3.1% 22.8% 3.4% 14.1% 18.8% 9.8% 1.5% 5.9% 4.7% S11N13 10.6% 5.5% 17.5% 3.5% 8.4% 13.6% 2.8% 0.9% 4.9% 3.8% S11N15 12.5% 1.3% 24.5% 9.0% 9.9% 8.2% 5.2% 0.1% 7.0% 7.0% S11N16 8.2% 3.5% 13.8% 4.4% 6.8% 5.7% 1.7% 0.4% 6.6% 3.9% S11N18 13.8% 2.8% 32.1% 4.4% 9.3% 21.7% 3.4% 4.4% 9.3% 5.7% S11.sup.2N12 0.0% 0.0% 0.0% 0.0% 0.1% 0.3% 0.1% 0.0% 0.0% 0.0% S12N6 0.3% 0.1% 0.0% 0.0% 0.2% 1.1% 6.5% 0.1% 0.3% 0.1% S12N7 6.9% 0.1% 3.2% 0.2% 3.6% 11.2% 3.4% 0.3% 0.3% 5.8% S12N8 6.0% 0.1% 1.5% 0.0% 13.8% 43.1% 0.1% 0.0% 8.9% 16.3% S12N9 4.5% 0.0% 7.0% 0.1% 20.2% 37.0% 0.8% 0.0% 10.9% 11.3% S12N11 3.2% 0.3% 30.3% 1.0% 8.0% 14.9% 5.8% 0.0% 3.9% 19.6% S12N12 7.9% 0.0% 31.4% 0.1% 3.5% 9.1% 3.7% 0.0% 5.1% 9.3% S12N13 1.4% 0.0% 3.6% 0.5% 1.5% 7.0% 12.9% 0.0% 2.1% 2.4% S12N15 0.8% 0.0% 2.0% 1.0% 0.2% 0.9% 3.6% 0.0% 0.2% 4.0% S12N16 0.5% 0.0% 2.6% 0.7% 0.7% 2.1% 3.6% 0.0% 0.4% 2.4% S12N18 0.7% 0.0% 3.9% 0.3% 0.6% 0.6% 0.3% 0.0% 0.2% 3.7% S12.sup.2N12 0.0% 0.0% 0.0% 0.0% 0.3% 0.3% 0.1% 0.0% 0.1% 0.1% S14N6 24.1% 18.8% 23.6% 2.5% 21.7% 30.1% 20.3% 13.6% 17.4% 39.0% S14N7 12.5% 18.7% 14.4% 3.7% 16.3% 25.0% 10.5% 13.3% 16.1% 34.6% S14N8 8.9% 12.9% 24.4% 2.6% 19.6% 33.4% 1.6% 9.8% 15.7% 26.2% S14N9 20.8% 9.7% 30.7% 2.0% 16.9% 43.9% 10.6% 10.7% 16.7% 17.6% S14N11 11.8% 12.5% 25.2% 3.1% 13.3% 17.0% 8.6% 2.2% 10.2% 9.0% S14N12 15.3% 1.6% 21.0% 3.8% 9.8% 6.3% 1.1% 2.1% 4.1% 5.8% S14N13 1.1% 0.0% 9.1% 3.9% 1.9% 2.6% 2.8% 0.3% 1.4% 2.2% S14N15 0.4% 0.1% 1.0% 0.4% 0.4% 0.8% 1.1% 0.3% 0.7% 0.7% S14N16 0.7% 0.0% 1.3% 1.9% 0.9% 0.8% 1.3% 0.1% 0.9% 0.7% S14N18 0.9% 0.0% 1.7% 0.7% 0.6% 0.9% 1.2% 0.1% 0.3% 0.1% S14.sup.2N12 0.3% 0.0% 0.2% 0.0% 0.0% 0.2% 0.1% 0.0% 0.0% 0.0% S15N6 21.2% 34.1% 32.4% 21.6% 14.9% 34.2% 5.1% 19.8% 15.4% 26.5% S15N7 18.2% 23.0% 19.7% 8.1% 12.9% 32.1% 13.3% 14.5% 17.1% 33.4% S15N8 8.9% 19.3% 12.7% 3.0% 17.3% 23.9% 6.7% 7.9% 11.6% 19.4% S15N9 21.3% 9.7% 30.1% 4.5% 17.5% 23.1% 16.4% 10.1% 13.4% 35.1% S15N11 12.9% 19.3% 20.9% 8.9% 11.8% 12.9% 9.3% 6.1% 11.9% 16.6% S15N12 4.9% 0.0% 11.5% 0.1% 5.7% 6.4% 5.9% 1.5% 3.3% 4.3% S15N13 0.4% 0.0% 4.2% 0.0% 1.9% 2.7% 5.5% 0.2% 3.2% 0.0% S15N15 0.6% 0.0% 0.8% 0.5% 0.4% 0.0% 0.4% 0.1% 0.5% 0.3% S15N16 1.3% 0.0% 0.6% 0.4% 0.2% 0.0% 0.4% 0.0% 0.2% 0.3% S15N18 0.6% 0.0% 0.7% 0.4% 0.3% 0.3% 0.9% 0.3% 0.4% 1.2% S15.sup.2N12 0.0% 0.0% 0.1% 0.0% 0.7% 0.0% 0.2% 0.0% 0.9% 1.0% S16N6 8.0% 16.5% 35.3% 6.0% 18.7% 24.1% 5.8% 11.6% 9.6% 14.5% S16N7 13.0% 16.6% 8.9% 6.9% 10.1% 12.9% 7.3% 12.0% 9.8% 3.4% S16N8 10.0% 14.6% 13.2% 8.4% 6.7% 11.1% 4.6% 16.5% 10.9% 14.9% S16N9 7.5% 7.4% 13.7% 9.1% 7.8% 11.7% 5.3% 6.7% 9.5% 6.9% S16N11 17.2% 9.6% 16.6% 5.8% 9.5% 10.3% 15.5% 5.0% 9.6% 0.0% S16N12 4.2% 0.0% 3.9% 0.0% 1.9% 2.7% 0.7% 0.0% 11.4% 2.1% S16N13 1.2% 0.0% 1.5% 0.0% 0.8% 1.2% 3.7% 0.2% 5.7% 2.0% S16N15 1.6% 0.0% 0.0% 2.6% 0.3% 0.0% 0.6% 0.0% 0.3% 0.2% S16N16 0.7% 0.0% 1.6% 3.4% 0.5% 0.1% 0.2% 0.0% 0.0% 0.2% S16N18 0.3% 0.0% 0.6% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 1.2% S16.sup.2N12 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.0% 0.6% 0.3% S18N6 6.9% 5.9% 22.1% 7.2% 18.1% 14.5% 10.4% 5.5% 11.0% 8.9% S18N7 6.8% 3.2% 15.6% 3.5% 28.2% 20.7% 4.5% 3.9% 9.3% 13.5% S18N8 4.1% 3.8% 9.6% 3.9% 13.6% 23.0% 6.7% 2.0% 6.6% 11.7% S18N9 5.3% 3.4% 20.4% 4.0% 7.7% 19.5% 6.7% 3.0% 0.0% 4.5% S18N11 3.7% 1.4% 4.2% 10.1% 6.3% 5.2% 2.7% 1.3% 2.9% 2.7% S18N12 1.3% 0.7% 1.8% 0.3% 1.0% 0.5% 0.5% 0.0% 0.0% 5.3% S18N13 1.3% 0.0% 2.8% 0.0% 0.0% 2.6% 0.0% 0.0% 1.8% 0.9% S18N15 0.2% 0.0% 0.2% 0.2% 0.0% 0.0% 0.1% 0.0% 0.1% 0.2% S18N16 0.0% 0.0% 0.1% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0% 0.1% S18N18 0.1% 0.1% 0.0% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% S18.sup.2N12 0.0% 0.0% 0.2% 0.0% 0.0% 1.6% 0.0% 0.0% 0.0% 0.4% S6S6 1.1% 0.4% 4.4% 1.4% 9.1% 12.5% 23.0% 0.8% 7.6% 21.6% S6S7 0.5% 1.2% 1.4% 2.0% 5.7% 6.9% 22.2% 0.0% 7.5% 21.6% S6S8 1.9% 2.5% 2.8% 1.3% 15.3% 7.4% 15.0% 0.6% 10.0% 24.1% S6S9 2.6% 9.1% 6.9% 1.8% 13.7% 7.1% 10.2% 2.0% 8.4% 18.0% S6S10 3.2% 8.3% 4.4% 4.5% 12.4% 20.9% 7.7% 0.0% 7.9% 14.9% S6S11 6.0% 18.7% 12.4% 6.2% 32.7% 32.1% 10.1% 4.5% 16.8% 38.1% S6S12 6.3% 5.0% 4.3% 3.0% 28.8% 13.6% 6.6% 7.5% 9.4% 24.4% S6S14 8.3% 11.1% 9.2% 12.0% 18.6% 21.9% 4.7% 2.3% 4.1% 53.3% S6S15 5.5% 8.4% 14.5% 7.9% 13.7% 36.4% 3.3% 11.5% 8.3% 34.5% S6S16 8.4% 24.0% 9.8% 7.9% 15.2% 0.4% 3.7% 0.0% 3.9% 37.6% S6S18 9.8% 8.1% 13.8% 10.4% 15.1% 0.0% 6.4% 15.9% 8.7% 34.7% S7S7 7.9% 2.2% 9.2% 0.0% 4.8% 10.3% 9.3% 0.6% 7.9% 5.5% S7S8 6.7% 0.0% 9.2% 7.0% 11.2% 3.6% 5.8% 3.7% 10.2% 0.0% S7S9 10.8% 28.8% 21.5% 15.1% 12.5% 3.4% 14.5% 12.2% 17.1% 16.3% S7S10 21.8% 23.6% 19.4% 8.1% 10.6% 4.7% 20.2% 18.0% 23.9% 25.2% S7S11 10.8% 27.3% 9.7% 14.2% 32.4% 28.7% 10.4% 11.1% 25.9% 39.1% S7S12 8.2% 18.0% 9.9% 9.5% 9.6% 11.7% 7.1% 10.9% 4.8% 21.3% S7S14 7.7% 15.9% 8.4% 9.1% 10.7% 4.4% 4.0% 11.0% 3.8% 26.7% S7S15 9.4% 24.0% 4.6% 11.6% 14.9% 7.6% 5.0% 10.9% 1.6% 33.3% S7S16 10.0% 17.6% 6.3% 10.9% 7.9% 9.0% 3.5% 12.8% 2.3% 22.2% S7S18 3.7% 7.1% 11.2% 8.3% 14.2% 5.5% 7.3% 16.1% 13.1% 48.9% S8S8 17.9% 17.6% 10.4% 11.2% 10.2% 5.1% 10.1% 13.8% 12.1% 27.9% S8S9 15.6% 37.0% 15.1% 13.2% 5.8% 6.3% 29.3% 16.0% 23.5% 27.9% S8S10 16.3% 18.8% 8.9% 8.3% 19.5% 9.3% 11.4% 13.7% 25.6% 26.2% S8S11 9.2% 17.9% 6.1% 8.5% 10.6% 7.9% 10.3% 15.3% 12.8% 42.4% S8S12 10.7% 16.1% 10.9% 10.8% 24.8% 12.6% 9.3% 34.4% 3.5% 23.5% S8S14 8.3% 18.5% 13.9% 9.3% 29.9% 16.2% 7.5% 17.1% 16.0% 41.1% S8S15 8.1% 10.8% 21.8% 11.2% 31.2% 24.5% 13.8% 23.0% 13.9% 32.1% S8S16 4.6% 15.7% 20.7% 10.2% 3.7% 33.0% 11.8% 28.6% 6.7% 75.2% S8S18 7.6% 0.9% 14.3% 15.8% 9.6% 8.2% 9.2% 18.7% 17.7% 19.3% S9S9 12.9% 6.8% 11.9% 14.5% 12.5% 5.6% 32.6% 19.1% 19.3% 11.3% S9S10 8.6% 10.7% 10.3% 13.3% 27.6% 21.2% 8.3% 22.5% 34.1% 18.7% S9S11 9.5% 17.3% 10.0% 15.2% 11.4% 41.9% 8.1% 21.8% 8.5% 32.8% S9S12 14.6% 16.7% 4.9% 0.0% 21.0% 20.2% 5.3% 30.4% 39.3% 17.9% S9S14 2.1% 14.3% 5.1% 7.2% 14.6% 19.2% 12.5% 21.0% 28.4% 14.5% S9S15 2.1% 10.6% 2.5% 11.8% 8.9% 47.4% 5.0% 22.2% 25.3% 56.1% S9S16 0.0% 1.5% 0.0% 12.2% 23.5% 55.4% 8.4% 23.2% 13.9% 56.9% S9S18 4.9% 2.3% 13.9% 5.5% 4.0% 1.7% 11.8% 27.0% 0.0% 7.0% S10S10 7.8% 4.0% 13.6% 5.5% 14.7% 23.6% 7.2% 14.0% 13.4% 18.8% S10S11 7.0% 2.2% 6.8% 16.7% 8.4% 8.2% 7.3% 16.4% 13.6% 13.3% S10S12 6.6% 2.4% 8.2% 12.0% 9.8% 16.2% 7.2% 20.9% 28.1% 13.7% S10S14 8.5% 1.5% 7.9% 5.9% 15.7% 26.9% 2.6% 18.9% 3.9% 23.0% S10S15 6.8% 7.7% 7.6% 7.5% 3.7% 32.8% 7.2% 15.2% 3.9% 55.8% S10S16 7.2% 0.1% 9.5% 9.1% 9.4% 14.1% 3.1% 15.7% 7.8% 79.4% S10S18 9.9% 1.6% 11.1% 6.7% 3.7% 22.4% 9.2% 13.7% 6.5% 43.1% S11S11 1.3% 0.2% 6.5% 4.0% 3.4% 10.9% 0.0% 3.6% 4.3% 12.2% S11S12 2.3% 0.1% 5.4% 5.6% 2.8% 5.2% 3.1% 10.7% 2.4% 4.8% S11S14 2.0% 0.7% 6.7% 3.7% 5.1% 6.6% 2.9% 8.8% 4.1% 58.1% S11S15 0.9% 0.3% 7.4% 5.3% 4.8% 4.8% 5.3% 3.0% 1.8% 42.3% S11S16 0.5% 0.0% 6.2% 1.7% 4.9% 2.7% 2.2% 4.7% 3.6% 49.0% S11S18 0.6% 0.2% 4.8% 3.3% 1.7% 3.6% 3.6% 7.8% 0.9% 20.9% S12S12 0.5% 0.1% 2.1% 4.1% 0.4% 3.9% 3.3% 3.4% 1.9% 2.7% S12S14 0.6% 0.1% 6.5% 6.7% 0.2% 4.0% 3.3% 3.7% 0.8% 6.5% S12S15 0.8% 0.5% 2.9% 3.8% 0.1% 4.4% 1.4% 3.1% 2.0% 9.9% S12S16 0.6% 0.0% 2.0% 3.3% 0.1% 2.7% 0.7% 0.2% 0.5% 7.3% S12S18 0.0% 0.0% 2.1% 2.6% 0.7% 1.0% 0.7% 0.4% 1.0% 7.5% S14S14 0.1% 0.0% 0.2% 0.7% 0.0% 0.2% 2.3% 0.0% 0.0% 0.9% S14S15 0.1% 0.1% 0.3% 0.7% 0.0% 0.2% 0.6% 0.0% 0.0% 0.3% S14S16 0.0% 0.0% 0.4% 0.6% 0.1% 1.2% 1.1% 0.0% 0.0% 2.7% S14S18 0.0% 0.2% 2.8% 2.5% 0.2% 1.2% 0.9% 0.2% 0.5% 1.7% S15S15 1.0% 0.0% 0.0% 1.5% 0.3% 0.4% 0.6% 0.0% 0.4% 1.0% S15S16 1.7% 0.0% 0.1% 2.0% 0.2% 0.2% 0.6% 0.0% 0.3% 0.6% S15S18 0.0% 0.1% 2.6% 0.3% 0.3% 1.0% 1.5% 0.0% 0.3% 0.3% S16S16 0.6% 1.1% 0.9% 1.2% 0.0% 0.5% 0.5% 0.0% 0.5% 0.1% S16S18 1.2% 0.0% 1.9% 0.3% 1.7% 0.2% 1.0% 0.3% 0.4% 0.8% S18S18 0.0% 0.0% 0.1% 0.1% 0.1% 0.2% 0.2% 0.0% 0.9% 0.0% N6N6 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% N6N7 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% N6N8 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% N6N9 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% N6N11 0.0% 0.0% 0.3% 0.0% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0% N6N12 0.0% 0.0% 0.2% 0.0% 0.1% 0.3% 0.0% 0.0% 0.0% 0.2% N6N13 0.0% 0.0% 0.5% 0.0% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% N6N15 0.0% 0.0% 0.6% 0.1% 0.0% 0.3% 0.0% 0.3% 0.1% 0.2% N6N16 0.4% 0.0% 0.7% 0.0% 0.0% 0.2% 0.0% 0.6% 0.0% 0.7% N6N18 1.1% 0.6% 3.4% 2.0% 0.6% 1.8% 0.9% 0.3% 0.1% 0.4% N6.sup.2N12 0.6% 0.2% 0.4% 0.2% 0.2% 0.4% 0.1% 0.0% 0.0% 0.4% N7N7 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% N7N8 0.2% 0.0% 0.5% 0.2% 0.0% 0.0% 0.0% 0.0% 0.7% 0.0% N7N9 0.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 0.4% N7N11 1.3% 0.1% 1.0% 1.4% 0.6% 1.1% 0.0% 0.0% 0.1% 0.7% N7N12 0.2% 0.0% 3.5% 0.0% 0.3% 0.4% 0.0% 0.1% 0.1% 1.4% N7N13 1.0% 0.1% 0.0% 0.0% 0.9% 1.6% 0.1% 0.0% 1.3% 1.6% N7N15 1.0% 0.0% 5.2% 0.2% 0.0% 1.6% 0.0% 0.2% 0.6% 0.6% N7N16 0.9% 0.0% 2.3% 0.0% 0.3% 0.6% 0.0% 0.1% 0.0% 1.8% N7N18 1.0% 0.0% 5.0% 0.2% 0.7% 0.7% 0.0% 0.2% 2.1% 15.6% N7.sup.2N12 3.6% 1.7% 2.5% 1.2% 0.9% 0.7% 0.6% 1.6% 1.9% 1.4% N8N8 2.3% 0.0% 1.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.7% 0.0% N8N9 0.0% 0.0% 0.5% 0.0% 0.0% 0.4% 0.0% 0.0% 0.0% 0.5% N8N11 0.4% 0.0% 3.6% 0.2% 0.2% 0.3% 0.0% 0.0% 0.0% 0.3% N8N12 0.6% 0.0% 2.4% 0.0% 0.6% 0.4% 0.0% 0.0% 0.0% 0.7% N8N13 2.2% 0.0% 0.9% 0.7% 0.0% 0.0% 0.0% 0.0% 1.0% 2.1% N8N15 1.5% 0.0% 1.5% 0.5% 0.6% 1.3% 0.0% 1.1% 0.0% 3.2% N8N16 3.8% 0.8% 8.5% 5.3% 0.2% 2.4% 3.1% 2.3% 1.0% 3.4% N8N18 1.8% 1.7% 9.8% 8.2% 1.9% 2.2% 2.7% 1.3% 1.2% 1.4% N8.sup.2N12 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.2% 0.2% 0.0% N9N9 0.2% 0.0% 0.3% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% N9N11 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% N9N12 0.0% 0.0% 0.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% N9N13 0.4% 0.0% 1.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.3% N9N15 0.5% 0.0% 0.5% 0.0% 0.2% 0.0% 0.0% 0.2% 0.9% 0.0% N9N16 2.1% 0.0% 2.2% 0.8% 0.0% 2.2% 0.0% 1.8% 0.0% 4.8% N9N18 4.0% 3.6% 2.0% 19.9% 0.0% 2.2% 3.0% 1.4% 0.3% 2.6% N9.sup.2N12 0.0% 0.0% 0.4% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% N11N11 0.9% 0.0% 1.8% 0.0% 0.9% 0.7% 0.6% 0.0% 0.0% 0.5% N11N12 0.0% 0.5% 1.9% 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 1.8% N11N13 1.4% 0.0% 0.0% 0.0% 0.1% 0.8% 0.5% 0.0% 0.0% 0.0% N11N15 1.3% 0.3% 0.3% 0.9% 0.2% 1.6% 0.2% 1.1% 0.1% 0.4% N11N16 0.4% 0.0% 1.2% 0.1% 0.0% 0.2% 0.0% 0.0% 0.0% 0.6% N11N18 3.4% 0.3% 0.6% 1.9% 1.4% 0.4% 1.1% 2.2% 0.0% 0.2% N112N12 0.7% 0.0% 1.1% 0.5% 1.2% 0.1% 0.4% 0.0% 0.1% 0.7% N12N12 0.1% 0.2% 1.9% 0.4% 0.4% 0.3% 0.1% 0.0% 0.0% 0.5% N12N13 1.2% 0.1% 1.7% 0.0% 0.3% 0.5% 0.2% 0.3% 0.3% 0.2% N12N15 1.5% 0.3% 1.1% 1.4% 0.4% 0.9% 0.8% 1.4% 1.5% 0.7% N12N16 2.6% 0.9% 1.2% 1.2% 0.1% 1.9% 0.4% 0.7% 0.9% 0.0% N12N18 1.4% 0.6% 3.5% 0.9% 0.0% 1.5% 1.2% 1.5% 0.1% 0.0% N12.sup.2N12 0.5% 0.4% 3.2% 2.5% 0.5% 3.6% 2.2% 0.6% 3.0% 0.7% N13N13 1.5% 0.0% 0.7% 1.5% 0.9% 2.5% 0.1% 1.4% 1.1% 0.3% N13N15 1.5% 0.0% 1.4% 0.0% 0.2% 0.3% 0.8% 0.0% 0.2% 0.0% N13N16 0.8% 0.0% 0.4% 1.0% 0.0% 1.0% 1.5% 0.0% 0.0% 0.0% N13N18 2.7% 0.2% 0.5% 1.8% 0.2% 3.0% 3.7% 0.0% 1.1% 0.5% N13.sup.2N12 1.2% 0.1% 0.6% 0.8% 0.0% 1.3% 0.2% 0.0% 1.7% 0.0% N15N15 2.3% 0.0% 1.8% 1.3% 0.9% 1.5% 0.5% 0.0% 0.4% 1.1% N15N16 1.8% 0.0% 2.5% 1.9% 0.7% 0.8% 0.9% 0.0% 2.1% 1.5% N15N18 0.0% 0.0% 3.0% 1.6% 0.0% 0.6% 3.2% 0.9% 0.7% 3.5% N15.sup.2N12 0.9% 0.5% 2.4% 2.1% 2.8% 6.3% 1.3% 0.9% 1.7% 0.0% N16N16 1.3% 0.2% 1.4% 0.9% 0.0% 0.9% 0.0% 0.5% 1.9% 0.0% N16N18 1.2% 1.2% 0.4% 0.6% 1.1% 0.0% 0.0% 0.0% 0.0% 3.0% N16.sup.2N12 0.0% 0.4% 2.0% 3.2% 0.6% 0.5% 1.1% 0.4% 0.5% 1.5% N18N18 1.9% 0.0% 2.0% 0.9% 1.1% 0.3% 0.3% 0.1% 0.0% 0.0% N18.sup.2N12 1.0% 0.0% 1.5% 0.9% 0.7% 1.3% 0.2% 0.4% 0.6% 0.7% .sup.2N12.sup.2N12 0.4% 0.0% 1.3% 0.0% 0.0% 0.0% 0.0% 0.1% 0.2% 1.8% Lipofectamine2000 26.5%

Example 5: Preliminary Screening of Amino Lipid Compounds as mRNA Vectors

[0253] Cell line: HEK293 cells (ATCC CRL-1573™)

[0254] Medium: DMEM supplemented with 10% fetal bovine serum (Invitrogen)

[0255] Screening: cell transfection on 96-well plates

[0256] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). Lipofectamine2000 (Invitrogen) was used as the positive control.

[0257] Method: the experimental method was basically the same with Example 4, and the mass of EGFP mRNA (TriLink) for transfection was 50 ng per well.

[0258] Results: the absolute mRNA transfection efficiency in HEK293 cells for 2530 compounds is shown in Table 9.

TABLE-US-00015 TABLE 9 Absolute mRNA transfection efficiency in HEK293 cells for 2530 compounds. D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 S6N6 0.8% 0.4% 0.1% 0.3% 2.1% 0.0% 1.2% 0.0% 1.5% 0.3% S6N7 2.3% 2.7% 0.2% 0.0% 4.3% 0.2% 0.0% 0.4% 2.6% 5.5% S6N8 3.1% 0.0% 0.0% 0.3% 5.9% 0.4% 3.5% 0.2% 2.5% 1.4% S6N9 1.8% 0.8% 0.3% 1.1% 2.0% 0.3% 2.4% 1.2% 0.9% 1.2% S6N11 1.0% 0.8% 0.7% 0.9% 5.3% 2.5% 3.8% 1.1% 11.9% 4.0% S6N12 0.0% 0.8% 4.1% 0.7% 4.4% 3.5% 1.4% 2.0% 4.9% 9.6% S6N13 1.8% 0.2% 7.7% 2.1% 7.2% 3.0% 2.6% 0.0% 6.6% 22.7% S6N15 3.6% 1.2% 14.4% 0.4% 16.4% 12.1% 2.2% 0.1% 11.9% 7.9% S6N16 3.3% 2.2% 37.3% 0.5% 35.4% 40.4% 3.0% 0.6% 29.6% 41.5% S6N18 32.7% 4.5% 32.5% 1.8% 16.6% 60.1% 4.6% 0.7% 24.0% 41.4% S6.sup.2N12 0.7% 0.0% 0.4% 2.2% 0.3% 0.0% 0.2% 0.0% 0.1% 0.1% S7N6 5.1% 1.2% 5.8% 4.5% 1.9% 8.8% 2.3% 1.8% 0.8% 2.0% S7N7 4.4% 1.1% 6.6% 3.4% 1.0% 1.8% 3.9% 1.4% 2.5% 0.9% S7N8 2.0% 1.0% 1.3% 0.5% 4.3% 2.8% 3.5% 1.8% 1.7% 1.3% S7N9 10.0% 8.7% 2.8% 4.9% 3.1% 5.9% 10.5% 10.6% 5.2% 4.6% S7N11 5.8% 16.0% 9.6% 1.0% 8.2% 18.9% 11.1% 20.1% 13.8% 25.3% S7N12 5.4% 3.0% 6.5% 0.6% 23.0% 12.5% 3.6% 2.3% 62.7% 63.7% S7N13 12.8% 6.2% 19.1% 0.7% 39.5% 44.9% 1.2% 5.8% 60.4% 70.8% S7N15 21.3% 3.1% 33.7% 2.6% 38.5% 37.9% 18.5% 2.8% 32.6% 67.3% S7N16 29.5% 2.6% 25.0% 1.3% 32.2% 44.8% 12.8% 1.2% 29.3% 44.3% S7N18 35.7% 5.2% 39.8% 7.9% 38.5% 49.2% 16.7% 3.0% 37.1% 45.8% S7.sup.2N12 0.7% 0.4% 0.4% 1.0% 0.2% 0.9% 1.2% 0.6% 1.0% 1.4% S8N6 2.4% 0.7% 2.6% 2.7% 1.6% 9.4% 0.8% 1.0% 0.7% 0.4% S8N7 2.0% 0.9% 0.7% 1.8% 2.5% 4.3% 0.7% 0.1% 1.4% 0.3% S8N8 5.8% 0.9% 3.0% 0.6% 1.3% 3.5% 2.5% 1.3% 4.5% 1.2% S8N9 21.4% 8.3% 3.2% 2.3% 11.2% 6.7% 9.5% 3.5% 57.0% 30.2% S8N11 9.0% 8.1% 6.6% 0.3% 30.1% 32.3% 9.0% 7.9% 81.7% 81.5% S8N12 17.9% 7.0% 24.6% 3.5% 52.5% 46.0% 9.5% 3.8% 57.6% 73.1% S8N13 15.5% 7.5% 35.8% 4.5% 44.2% 58.0% 14.2% 1.5% 46.5% 75.0% S8N15 23.8% 5.5% 21.8% 2.6% 14.9% 55.3% 15.7% 4.6% 37.8% 53.3% S8N16 22.5% 3.4% 14.3% 1.9% 32.3% 67.0% 16.8% 4.9% 21.2% 36.4% S8N18 19.3% 3.7% 28.6% 3.5% 29.9% 40.4% 12.8% 1.2% 29.4% 20.1% S8.sup.2N12 0.4% 0.1% 0.9% 1.1% 0.9% 1.5% 1.3% 0.1% 0.6% 1.5% S9N6 1.1% 0.5% 0.2% 0.3% 2.9% 1.4% 0.6% 0.6% 1.8% 0.6% S9N7 0.3% 4.2% 1.4% 3.0% 2.6% 1.2% 1.6% 2.2% 2.8% 0.9% S9N8 2.9% 22.6% 10.4% 6.6% 6.0% 7.5% 11.1% 5.7% 9.2% 16.3% S9N9 8.0% 38.5% 15.4% 11.3% 38.2% 19.8% 17.8% 14.0% 76.1% 70.0% S9N11 53.0% 44.8% 47.8% 17.4% 32.1% 58.8% 36.8% 23.5% 49.2% 66.0% S9N12 30.2% 15.2% 49.6% 9.5% 24.6% 39.3% 25.6% 11.2% 36.0% 57.0% S9N13 25.8% 12.3% 58.2% 10.8% 41.5% 70.9% 33.4% 12.6% 20.0% 75.8% S9N15 27.4% 5.9% 67.9% 4.9% 32.9% 36.5% 11.7% 7.2% 6.3% 17.5% S9N16 25.6% 1.4% 50.3% 2.2% 16.1% 46.2% 10.9% 2.1% 16.7% 30.2% S9N18 47.6% 2.4% 26.7% 8.3% 28.6% 44.8% 21.1% 1.9% 14.5% 22.4% S9.sup.2N12 1.0% 0.1% 1.3% 0.1% 0.4% 1.7% 0.2% 0.3% 0.3% 7.7% S10N6 0.4% 0.1% 0.4% 0.1% 1.1% 1.5% 0.6% 0.2% 1.1% 0.5% S10N7 0.2% 0.5% 1.4% 0.1% 3.2% 4.4% 1.2% 0.6% 0.8% 1.0% S10N8 0.5% 0.5% 0.4% 0.1% 8.6% 3.7% 0.3% 0.4% 5.4% 1.7% S10N9 0.5% 0.5% 2.7% 0.2% 8.5% 8.7% 1.6% 0.1% 10.5% 4.2% S10N11 6.2% 0.2% 17.1% 0.8% 11.0% 10.0% 3.1% 0.1% 11.3% 8.8% S10N12 2.4% 1.5% 19.1% 1.0% 3.6% 25.4% 10.6% 0.1% 6.0% 15.5% S10N13 1.7% 0.2% 35.0% 0.3% 4.6% 10.2% 13.7% 0.2% 2.7% 8.5% S10N15 2.8% 1.3% 57.6% 1.5% 1.8% 3.5% 2.0% 0.2% 5.4% 13.2% S10N16 40.7% 0.6% 56.7% 14.7% 3.9% 51.5% 19.3% 0.2% 13.6% 15.4% S10N18 4.8% 0.0% 59.6% 37.7% 2.3% 31.8% 25.9% 0.1% 9.0% 6.0% S10.sup.2N12 0.4% 0.0% 0.1% 0.1% 0.1% 0.1% 0.0% 0.0% 0.3% 0.2% S11N6 4.4% 5.4% 18.1% 2.7% 26.9% 1.7% 4.3% 2.8% 12.2% 6.8% S11N7 11.7% 8.5% 8.0% 2.3% 8.5% 29.1% 11.8% 3.1% 10.5% 18.2% S11N8 13.1% 2.4% 31.8% 4.3% 36.2% 16.8% 13.4% 0.3% 37.6% 46.1% S11N9 14.7% 2.5% 24.5% 4.2% 41.5% 45.1% 5.0% 1.6% 60.3% 87.7% S11N11 24.7% 0.6% 33.5% 2.0% 36.5% 35.5% 35.0% 3.6% 24.5% 27.7% S11N12 27.3% 3.1% 40.5% 8.9% 22.8% 15.9% 7.8% 1.0% 21.7% 24.7% S11N13 12.6% 1.9% 25.9% 15.4% 11.2% 10.0% 5.8% 3.1% 9.4% 10.4% S11N15 6.2% 2.8% 31.3% 17.0% 20.4% 13.1% 6.5% 0.5% 15.7% 18.6% S11N16 13.0% 1.1% 15.7% 12.3% 3.9% 6.2% 4.4% 0.7% 3.9% 10.4% S11N18 15.4% 0.0% 40.6% 8.8% 4.7% 14.6% 10.8% 0.6% 14.9% 9.6% S11.sup.2N12 0.0% 0.3% 0.0% 0.5% 0.6% 3.2% 0.7% 0.4% 0.0% 0.0% S12N6 0.0% 0.0% 0.0% 0.9% 0.3% 1.1% 2.1% 0.9% 0.2% 0.2% S12N7 1.5% 0.4% 9.2% 0.5% 9.9% 13.0% 13.1% 1.5% 0.6% 1.7% S12N8 11.3% 1.6% 12.3% 1.6% 22.6% 30.5% 3.0% 2.3% 20.1% 12.9% S12N9 34.2% 1.1% 39.9% 0.7% 26.5% 24.0% 7.4% 2.3% 25.6% 17.5% S12N11 2.6% 0.3% 21.2% 3.7% 1.1% 14.0% 4.4% 0.4% 3.3% 26.6% S12N12 1.7% 0.0% 10.8% 2.1% 3.5% 10.4% 3.7% 0.0% 0.9% 31.5% S12N13 1.2% 0.0% 0.3% 1.3% 0.4% 5.5% 4.9% 0.3% 1.0% 1.8% S12N15 0.5% 0.0% 1.5% 2.0% 0.8% 1.6% 1.3% 0.0% 0.0% 4.1% S12N16 0.0% 0.8% 1.9% 1.3% 3.7% 1.9% 6.3% 0.7% 1.2% 3.4% S12N18 0.0% 0.8% 3.5% 4.6% 0.0% 1.7% 1.1% 1.1% 0.2% 4.1% S12.sup.2N12 2.6% 0.1% 2.2% 0.5% 1.6% 2.4% 1.9% 3.4% 0.8% 3.4% S14N6 29.1% 8.8% 66.7% 3.0% 48.0% 59.9% 15.7% 9.2% 27.2% 41.9% S14N7 25.7% 4.5% 64.2% 4.5% 59.0% 90.8% 36.3% 3.1% 50.1% 55.0% S14N8 56.7% 3.7% 55.2% 3.2% 65.6% 80.6% 10.8% 1.6% 24.8% 43.8% S14N9 39.0% 7.4% 51.6% 4.0% 44.9% 65.8% 29.8% 2.3% 23.7% 54.2% S14N11 14.3% 3.5% 30.9% 3.8% 19.8% 20.1% 17.0% 2.0% 15.6% 21.4% S14N12 9.6% 2.1% 13.5% 12.6% 11.3% 17.0% 6.6% 1.3% 8.0% 6.9% S14N13 6.0% 1.1% 25.9% 14.5% 12.9% 5.2% 11.7% 1.4% 4.8% 11.7% S14N15 1.1% 0.0% 3.6% 1.7% 0.3% 0.1% 0.8% 0.0% 0.5% 3.3% S14N16 1.8% 0.1% 1.2% 1.4% 0.6% 0.5% 2.7% 0.4% 0.8% 3.0% S14N18 1.8% 0.1% 1.5% 2.2% 0.6% 0.7% 0.4% 0.3% 0.3% 2.6% S14.sup.2N12 0.1% 0.0% 0.2% 0.2% 0.9% 0.1% 0.1% 0.1% 0.1% 0.2% S15N6 37.7% 4.9% 33.2% 1.3% 45.9% 37.4% 2.7% 3.5% 30.7% 18.4% S15N7 66.1% 4.5% 80.8% 1.2% 25.2% 46.1% 27.8% 2.2% 15.9% 22.1% S15N8 98.3% 2.2% 17.0% 1.6% 94.7% 6.9% 18.0% 2.9% 10.8% 12.9% S15N9 96.3% 1.1% 15.4% 1.8% 22.3% 61.9% 9.4% 1.1% 18.5% 12.8% S15N11 11.9% 3.3% 23.2% 1.0% 12.7% 7.8% 5.0% 1.1% 9.2% 2.7% S15N12 4.8% 0.1% 7.5% 1.6% 4.3% 9.6% 4.7% 0.3% 4.4% 5.1% S15N13 1.5% 0.1% 3.0% 0.8% 1.5% 0.8% 5.2% 0.2% 2.0% 5.4% S15N15 0.3% 0.2% 2.6% 3.5% 0.7% 0.8% 1.8% 0.1% 0.2% 2.4% S15N16 3.2% 1.4% 7.6% 4.8% 1.4% 0.2% 0.5% 0.4% 2.7% 6.1% S15N18 3.8% 0.3% 8.5% 5.1% 1.7% 1.9% 0.8% 0.4% 0.3% 4.2% S15.sup.2N12 0.3% 0.4% 1.7% 0.2% 0.9% 2.9% 1.8% 2.9% 0.4% 14.3% S16N6 54.2% 23.6% 96.0% 2.6% 63.2% 96.4% 16.5% 18.2% 85.7% 86.9% S16N7 65.1% 10.0% 85.0% 0.8% 82.6% 88.3% 7.8% 17.7% 97.9% 29.6% S16N8 40.3% 19.1% 97.7% 1.3% 72.2% 91.5% 6.5% 17.8% 71.3% 70.4% S16N9 26.4% 7.2% 92.8% 1.0% 68.1% 76.1% 9.0% 2.1% 54.4% 49.2% S16N11 19.8% 4.1% 73.8% 0.5% 45.0% 63.0% 8.3% 3.6% 68.4% 37.8% S16N12 3.0% 1.2% 1.7% 0.1% 3.4% 2.0% 1.3% 0.9% 12.4% 9.2% S16N13 0.9% 0.0% 0.4% 0.1% 0.7% 0.5% 2.9% 0.1% 1.4% 7.1% S16N15 1.4% 0.2% 0.0% 0.1% 0.1% 0.1% 1.1% 0.0% 0.2% 2.6% S16N16 0.9% 0.0% 1.1% 3.6% 0.1% 0.1% 1.6% 0.0% 0.1% 2.8% S16N18 0.5% 0.0% 14.1% 6.3% 0.2% 0.0% 1.5% 0.0% 0.1% 3.0% S16.sup.2N12 0.0% 0.7% 0.2% 0.3% 0.1% 1.0% 0.8% 0.0% 2.7% 0.2% S18N6 42.6% 0.4% 58.9% 1.5% 73.2% 74.8% 19.5% 1.0% 55.4% 58.8% S18N7 63.0% 1.0% 97.2% 0.3% 67.7% 87.5% 6.5% 3.9% 86.6% 45.8% S18N8 38.0% 3.1% 93.3% 7.8% 33.4% 74.5% 9.8% 0.5% 25.8% 16.8% S18N9 30.3% 0.4% 72.3% 0.2% 11.6% 40.1% 1.9% 0.2% 7.6% 8.9% S18N11 1.3% 0.5% 30.9% 0.9% 1.1% 5.7% 10.7% 1.9% 4.3% 4.5% S18N12 2.3% 2.3% 5.2% 0.7% 1.7% 2.6% 0.3% 0.4% 1.7% 2.0% S18N13 0.2% 0.0% 1.0% 0.7% 1.4% 1.0% 1.5% 0.0% 0.0% 2.9% S18N15 0.5% 0.0% 0.1% 1.6% 0.1% 0.0% 0.3% 0.0% 0.0% 0.2% S18N16 0.1% 0.0% 0.5% 0.4% 0.1% 0.0% 0.3% 0.0% 0.1% 0.4% S18N18 0.0% 0.0% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% S18.sup.2N12 0.0% 0.0% 0.1% 0.3% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% S6S6 0.7% 2.2% 1.9% 0.9% 4.3% 12.6% 19.5% 0.0% 8.0% 14.4% S6S7 1.0% 0.6% 1.3% 1.2% 10.0% 11.3% 22.9% 1.5% 6.3% 19.7% S6S8 0.7% 5.0% 1.6% 0.5% 8.7% 21.1% 18.9% 0.2% 3.0% 6.6% S6S9 2.3% 6.3% 2.6% 0.7% 8.3% 10.6% 4.2% 5.0% 5.6% 14.7% S6S10 0.7% 4.6% 2.5% 0.3% 10.1% 31.4% 2.7% 4.2% 23.7% 22.4% S6S11 0.4% 7.4% 0.7% 0.0% 21.1% 15.7% 0.5% 1.5% 8.5% 15.9% S6S12 0.6% 1.5% 1.0% 0.2% 14.0% 24.7% 8.1% 11.1% 1.0% 41.2% S6S14 0.8% 6.6% 0.3% 5.3% 45.3% 62.8% 3.8% 6.8% 35.8% 54.4% S6S15 1.2% 6.9% 12.0% 2.0% 29.7% 47.0% 1.3% 2.8% 6.5% 40.0% S6S16 0.9% 16.0% 16.9% 5.1% 60.5% 34.4% 2.3% 43.1% 38.2% 85.5% S6S18 15.9% 12.1% 36.8% 8.8% 55.1% 83.3% 9.5% 12.6% 62.8% 72.8% S7S7 14.9% 4.9% 12.2% 13.5% 10.5% 29.3% 18.4% 5.0% 18.3% 19.3% S7S8 16.7% 35.6% 2.7% 5.9% 16.6% 6.3% 42.1% 5.0% 43.7% 32.9% S7S9 8.1% 37.7% 12.6% 3.7% 20.6% 14.3% 13.5% 18.6% 35.3% 33.5% S7S10 5.6% 32.4% 3.3% 2.7% 12.2% 18.1% 1.7% 11.4% 47.1% 55.8% S7S11 4.1% 24.2% 11.4% 8.0% 42.0% 68.6% 4.5% 23.1% 80.0% 60.8% S7S12 3.1% 19.2% 5.4% 9.2% 48.8% 93.8% 5.8% 20.7% 26.4% 80.4% S7S14 3.1% 11.0% 14.6% 8.3% 63.7% 59.7% 4.1% 21.2% 34.5% 88.7% S7S15 3.9% 17.5% 12.0% 6.7% 58.7% 90.0% 5.4% 25.2% 9.6% 90.4% S7S16 6.9% 13.9% 11.6% 8.8% 49.2% 90.8% 10.7% 22.7% 9.2% 73.7% S7S18 4.1% 5.1% 7.9% 4.5% 3.8% 22.0% 7.1% 26.7% 34.3% 90.5% S8S8 11.7% 54.5% 26.1% 9.9% 45.2% 45.6% 25.3% 48.2% 53.3% 50.8% S8S9 7.4% 84.9% 11.6% 14.3% 36.1% 59.9% 11.1% 47.2% 85.2% 37.6% S8S10 8.6% 38.8% 12.0% 9.2% 65.6% 70.2% 7.6% 40.9% 79.4% 74.2% S8S11 3.0% 43.3% 4.9% 10.9% 87.0% 92.3% 3.2% 22.2% 97.6% 67.0% S8S12 1.4% 1.1% 3.5% 1.0% 47.4% 61.9% 1.3% 67.9% 23.6% 67.9% S8S14 0.7% 0.4% 3.4% 3.1% 52.7% 79.5% 1.3% 3.4% 13.5% 60.5% S8S15 0.4% 0.0% 0.9% 2.6% 40.0% 45.0% 0.0% 8.0% 22.0% 64.0% S8S16 2.2% 0.2% 37.3% 2.1% 20.5% 61.0% 0.5% 4.4% 1.5% 98.3% S8S18 3.9% 0.0% 61.5% 2.0% 27.5% 19.1% 3.8% 4.2% 28.1% 59.6% S9S9 0.8% 3.1% 4.5% 2.1% 37.1% 33.0% 3.6% 14.8% 19.3% 34.9% S9S10 5.0% 2.5% 70.1% 4.1% 61.4% 74.6% 2.8% 9.8% 46.6% 47.2% S9S11 3.0% 3.3% 1.9% 4.1% 48.6% 85.1% 2.5% 24.4% 49.7% 88.8% S9S12 0.8% 0.0% 5.3% 0.6% 57.5% 61.6% 3.4% 13.8% 60.9% 82.9% S9S14 1.6% 0.3% 2.3% 0.7% 32.3% 80.0% 1.5% 11.6% 68.8% 91.0% S9S15 0.0% 0.0% 2.5% 2.1% 41.3% 87.2% 1.2% 5.4% 40.4% 94.8% S9S16 0.0% 0.0% 25.3% 1.2% 47.8% 71.5% 1.8% 11.2% 41.4% 66.4% S9S18 2.7% 0.0% 35.8% 0.6% 22.0% 11.6% 1.9% 12.4% 4.0% 43.6% S10S10 0.7% 0.4% 5.0% 2.5% 45.9% 59.1% 2.0% 13.8% 51.3% 87.1% S10S11 1.2% 0.6% 4.4% 0.0% 61.1% 83.8% 1.8% 8.3% 60.6% 93.7% S10S12 0.0% 0.0% 7.6% 3.4% 33.5% 82.4% 0.0% 5.4% 53.7% 91.0% S10S14 0.1% 0.2% 0.6% 0.2% 12.9% 48.6% 1.3% 7.5% 5.7% 37.7% S10S15 0.0% 0.7% 19.6% 0.7% 9.4% 24.6% 0.0% 11.1% 3.8% 19.4% S10S16 0.1% 0.3% 1.7% 0.8% 13.6% 41.6% 0.7% 4.0% 19.9% 47.4% S10S18 3.5% 0.2% 21.5% 6.2% 3.5% 19.9% 0.3% 8.0% 2.4% 54.6% S11S11 12.9% 0.0% 3.6% 0.4% 28.7% 25.4% 0.0% 1.4% 8.0% 13.7% S11S12 4.7% 0.0% 3.2% 0.4% 9.2% 21.5% 0.4% 6.7% 4.2% 10.5% S11S14 1.9% 0.0% 17.9% 0.2% 9.1% 30.0% 0.7% 4.2% 9.9% 38.5% S11S15 0.0% 0.0% 5.3% 0.9% 17.4% 15.4% 0.7% 2.1% 3.6% 75.9% S11S16 2.4% 0.1% 0.7% 0.2% 5.1% 9.3% 0.5% 0.9% 16.4% 89.2% S11S18 2.7% 0.1% 11.6% 1.4% 3.8% 6.0% 1.1% 3.3% 0.3% 92.0% S12S12 0.6% 0.0% 11.0% 36.3% 3.1% 2.6% 1.3% 3.8% 1.3% 12.8% S12S14 0.0% 0.2% 6.3% 14.0% 3.6% 4.6% 0.9% 1.3% 2.5% 30.4% S12S15 4.1% 0.0% 9.7% 3.3% 1.4% 0.0% 0.0% 3.2% 0.9% 43.1% S12S16 0.0% 0.0% 0.1% 6.3% 0.1% 1.2% 0.0% 0.0% 0.0% 13.2% S12S18 0.0% 0.0% 0.2% 5.1% 0.0% 0.1% 0.0% 0.0% 0.0% 7.7% S14S14 0.0% 0.0% 0.1% 0.8% 0.0% 0.2% 2.8% 0.0% 0.0% 1.5% S14S15 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.4% 0.0% 0.0% 0.5% S14S16 0.0% 0.0% 0.2% 0.0% 0.2% 0.9% 1.8% 0.0% 0.0% 0.8% S14S18 0.0% 0.0% 0.1% 0.8% 1.0% 0.2% 2.7% 0.3% 0.6% 1.5% S15S15 0.5% 0.0% 0.2% 1.5% 0.3% 0.9% 0.5% 0.2% 0.5% 0.3% S15S16 0.7% 0.7% 0.2% 3.2% 0.2% 0.4% 0.4% 0.0% 0.5% 0.6% S15S18 0.0% 0.5% 1.9% 0.0% 0.4% 0.0% 9.3% 0.5% 0.0% 1.8% S16S16 0.4% 0.2% 0.8% 2.2% 0.7% 0.5% 0.0% 1.7% 0.2% 2.7% S16S18 2.1% 0.0% 1.8% 0.3% 0.3% 1.8% 1.8% 1.9% 0.5% 3.0% S18S18 0.0% 0.1% 0.1% 0.1% 0.1% 0.5% 0.0% 0.0% 0.1% 0.0% N6N6 0.0% 0.0% 0.3% 0.1% 0.0% 0.0% 0.0% 0.0% 0.2% 0.0% N6N7 0.1% 0.4% 0.0% 0.0% 0.4% 0.1% 0.0% 0.0% 0.0% 0.0% N6N8 0.0% 0.1% 0.4% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% N6N9 0.0% 0.0% 0.4% 0.3% 0.1% 0.2% 0.0% 0.0% 0.0% 0.3% N6N11 0.1% 0.0% 0.9% 0.0% 0.5% 0.0% 0.0% 0.1% 0.0% 0.0% N6N12 0.2% 0.0% 0.5% 0.0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.0% N6N13 0.0% 0.0% 1.0% 0.6% 0.0% 0.1% 0.9% 0.0% 0.0% 0.0% N6N15 0.0% 0.1% 0.3% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.7% N6N16 0.0% 0.1% 2.8% 0.0% 0.1% 0.4% 0.5% 0.0% 0.0% 0.8% N6N18 3.9% 0.9% 3.9% 0.2% 0.0% 0.1% 0.3% 0.0% 0.2% 0.1% N6.sup.2N12 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.3% 0.0% 0.0% 0.0% N7N7 0.0% 0.0% 0.0% 0.0% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% N7N8 0.0% 0.3% 3.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 0.6% N7N9 0.0% 0.0% 0.1% 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.1% N7N11 0.0% 0.0% 1.3% 0.1% 0.1% 1.5% 0.0% 0.0% 0.0% 0.2% N7N12 0.1% 0.0% 6.3% 0.6% 0.0% 0.2% 0.0% 0.0% 0.0% 0.8% N7N13 0.4% 0.0% 7.8% 0.3% 0.9% 2.3% 0.0% 0.1% 0.1% 1.6% N7N15 1.3% 0.1% 3.8% 0.0% 0.0% 1.2% 0.0% 0.2% 0.7% 2.5% N7N16 0.5% 0.1% 1.3% 0.0% 0.0% 5.0% 0.4% 0.0% 0.0% 3.1% N7N18 2.3% 0.0% 0.1% 0.1% 0.1% 1.1% 0.0% 0.2% 0.5% 73.8% N7.sup.2N12 3.5% 0.9% 6.8% 3.7% 2.4% 4.8% 1.9% 2.7% 5.4% 2.0% N8N8 0.0% 0.0% 0.4% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% N8N9 0.8% 0.3% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% N8N11 0.0% 0.0% 4.2% 0.2% 0.4% 0.1% 0.0% 0.1% 0.0% 0.2% N8N12 0.5% 0.0% 0.5% 0.0% 0.9% 0.1% 0.0% 0.0% 0.0% 2.3% N8N13 0.0% 0.1% 2.7% 0.2% 0.0% 0.0% 0.0% 0.2% 0.0% 1.9% N8N15 0.7% 0.0% 7.6% 0.0% 0.2% 0.0% 0.0% 0.3% 0.1% 3.3% N8N16 4.6% 0.2% 13.8% 2.3% 0.3% 1.5% 0.3% 0.2% 0.5% 1.5% N8N18 6.4% 7.0% 39.9% 29.2% 0.9% 4.1% 9.3% 2.8% 0.0% 5.0% N8.sup.2N12 0.2% 1.4% 0.9% 0.2% 0.4% 0.9% 0.0% 2.0% 0.4% 2.7% N9N9 0.5% 0.1% 0.2% 0.6% 0.1% 0.4% 0.3% 0.6% 0.2% 0.8% N9N11 2.2% 0.3% 1.8% 0.0% 1.1% 0.5% 0.8% 0.4% 0.7% 0.0% N9N12 0.5% 0.8% 4.3% 2.4% 3.8% 0.2% 0.0% 0.0% 0.1% 0.4% N9N13 2.2% 0.6% 4.6% 0.5% 0.2% 0.4% 0.3% 0.0% 2.5% 2.8% N9N15 2.2% 0.2% 4.7% 0.6% 1.8% 1.7% 0.8% 1.4% 1.1% 1.7% N9N16 1.5% 0.7% 4.3% 4.5% 0.0% 6.2% 1.1% 0.0% 1.1% 1.2% N9N18 5.1% 25.3% 4.7% 1.3% 0.9% 2.5% 0.6% 0.3% 3.1% 1.9% N9.sup.2N12 4.7% 1.3% 2.3% 0.4% 1.8% 0.8% 0.2% 0.3% 3.9% 2.9% N11N11 4.3% 1.4% 1.4% 4.1% 0.4% 1.1% 5.5% 1.5% 0.3% 1.2% N11N12 0.3% 0.5% 2.7% 1.2% 8.0% 8.1% 2.4% 2.8% 0.3% 0.4% N11N13 5.9% 0.1% 3.6% 0.9% 0.2% 0.2% 0.9% 0.6% 7.1% 0.0% N11N15 0.6% 0.7% 2.7% 2.8% 0.8% 0.3% 0.0% 0.5% 0.3% 1.6% N11N16 0.6% 1.0% 3.6% 0.0% 2.5% 1.4% 0.7% 0.4% 0.9% 1.1% N11N18 7.2% 0.8% 2.8% 2.3% 0.0% 0.0% 4.0% 1.2% 1.7% 1.6% N1PN12 1.4% 0.3% 3.8% 2.5% 1.4% 0.5% 0.9% 1.5% 0.3% 1.3% N12N12 0.2% 1.0% 3.8% 2.2% 0.8% 0.8% 0.6% 0.3% 1.5% 0.6% N12N13 1.6% 0.0% 3.1% 0.0% 0.0% 1.0% 0.3% 0.0% 1.8% 0.2% N12N15 1.0% 0.4% 6.5% 1.3% 3.1% 2.3% 1.4% 0.9% 0.9% 1.2% N12N16 4.4% 0.0% 3.3% 0.7% 1.4% 1.9% 0.3% 0.9% 0.7% 0.6% N12N18 9.4% 0.9% 13.4% 1.9% 1.9% 4.8% 1.4% 0.5% 0.7% 1.0% N12.sup.2N12 2.8% 0.3% 5.8% 2.6% 2.2% 1.2% 2.0% 3.2% 0.7% 0.9% N13N13 0.4% 0.9% 3.5% 3.3% 1.7% 0.2% 1.1% 0.3% 0.2% 2.9% N13N15 1.4% 1.4% 4.7% 0.0% 0.8% 0.0% 3.7% 0.0% 0.5% 0.4% N13N16 1.5% 1.4% 1.6% 4.0% 0.4% 3.8% 0.6% 3.3% 1.4% 1.1% N13N18 13.8% 0.0% 21.5% 3.1% 0.7% 14.7% 1.3% 0.0% 0.8% 6.1% N13.sup.2N12 4.7% 0.5% 7.3% 4.5% 4.9% 3.9% 2.9% 2.3% 2.3% 0.0% N15N15 0.0% 0.0% 3.8% 0.8% 0.0% 0.0% 0.0% 0.0% 0.0% 4.2% N15N16 3.6% 0.0% 6.1% 1.6% 0.0% 1.3% 0.0% 0.0% 1.7% 0.0% N15N18 0.0% 0.0% 8.6% 1.9% 0.0% 8.6% 8.3% 0.0% 0.0% 7.4% N15.sup.2N12 0.0% 0.0% 0.0% 2.9% 3.7% 9.0% 0.0% 0.9% 0.0% 3.5% N16N16 9.5% 0.0% 2.8% 0.0% 0.0% 0.0% 7.9% 1.6% 0.0% 0.0% N16N18 0.0% 0.0% 20.8% 1.8% 0.0% 4.4% 0.0% 1.0% 0.0% 1.8% N16.sup.2N12 3.4% 0.0% 4.0% 0.0% 0.0% 0.0% 3.0% 4.3% 0.0% 0.0% N18N18 2.2% 0.0% 40.0% 0.0% 0.0% 4.4% 0.0% 0.0% 0.0% 0.0% N18.sup.2N12 0.4% 0.1% 3.4% 1.2% 0.7% 2.1% 0.7% 2.3% 0.6% 2.2% .sup.2N12.sup.2N12 0.1% 1.9% 0.0% 2.6% 2.7% 0.2% 0.3% 0.0% 0.0% 3.3% Lipofectamine2000 42.7%

Example 6: Transfection of Hela Cell Line with Amino Lipid Compounds as DNA Vectors

[0259] Cell line: Hela cells (ATCC 35241)

[0260] Medium: DMEM supplemented with 10% fetal bovine serum (Invitrogen)

[0261] Screening: cell transfection on 96-well plates

[0262] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). Lipofectamine2000 (Invitrogen) was used as the positive control, according to the manufacturer's instructions.

[0263] Method: the experimental method was basically the same with Example 4.

[0264] Results: the absolute DNA transfection efficiency in Hela cells for 170 compounds is shown in Table 10.

TABLE-US-00016 TABLE 10 Absolute DNA transfection efficiency in Hela cells for 170 compounds. D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 S8N11 21.12% 12.7% 26.2% 7.6% 26.5% 50.1% 12.2% 6.8% 31.9% 23.4% S8N12 11.5% 19.3% 8.8% 3.81% 20.8% 39.3% 4.7% 8.4% 24.4% 22.6% S8N13 9.7% 9.83% 15.7% 1.8% 14.7% 27.6% 4.5% 6.6% 13.9% 9.5% S9N9 17.7% 12.0% 27.4% 8.9% 23.9% 30.3% 24.8% 7.4% 25.6% 17.6% S9N11 17.7% 8.2% 21.8% 4.4% 22.5% 27.7% 7.8% 13.9% 24.3% 21.2% S9N12 19.7% 6.5% 23.7% 4.1% 24.1% 35.5% 6.8% 6.8% 14.4% 12.9% S11N7 13.9% 5.8% 9.8% 2.3% 11.4% 17.0% 5.8% 6.7% 8.3% 14.7% S11N8 9.9% 9.3% 12.9% 2.9% 9.6% 18.4% 5.7% 6.1% 11.7% 16.7% S11N9 6.0% 6.8% 11.5% 0.5% 10.6% 20.3% 0.9% 4.3% 11.8% 16.2% S7S11 5.9% 13.6% 4.8% 7.9% 16.8% 14.5% 5.2% 5.6% 12.9% 19.7% S7S12 4.2% 9.2% 4.9% 4.7% 4.9% 5.8% 3.5% 5.4% 2.9% 10.6% S8S11 4.59% 8.9% 3.3% 4.5% 5.9% 3.9% 5.7% 7.6% 6.8% 21.8% S8S12 5.4% 8.7% 5.5% 5.4% 12.4% 6.3% 4.6% 17.2% 1.7% 11.7% S9S12 7.9% 8.5% 2.4% 0.0% 10.8% 10.9% 2.7% 15.8% 19.6% 8.9% S9S14 1.4% 7.3% 2.4% 3.6% 7.3% 9.6% 6.5% 10.8% 14.8% 7.2% S9S15 1.3% 5.9% 1.4% 5.8% 4.4% 23.7% 2.8% 11.1% 12.6% 28.7% S9S16 0.0% 0.7% 0.0% 6.2% 11.7% 27.8% 4.2% 11.6% 6.9% 28.6% Lipofectamine2000 12.6%

Example 7: Transfection of Hela Cell Line with Amino Lipid Compounds as mRNA Vectors

[0265] Cell line: Hela cells (ATCC 35241)

[0266] Medium: DMEM supplemented with 10% fetal bovine serum (Invitrogen)

[0267] Screening: cell transfection on 96-well plates

[0268] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). A commercially available liposome transfection reagent Lipofectamine2000 (Invitrogen) was used as the positive control group, according to the manufacturer's instructions.

[0269] Method: the experimental method was basically the same with Example 4, and the mass of EGFP mRNA for transfection was 50 ng per well.

[0270] Results: the absolute mRNA transfection efficiency in Hela cells for 170 compounds is shown in Table 11.

TABLE-US-00017 TABLE 11 Absolute mRNA transfection efficiency in Hela cells for 170 compounds. D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 S8N11 21.2% 12.7% 26.2% 7.6% 26.5% 50.2% 12.3% 6.8% 31.9% 23.4% S8N12 11.5% 19.3% 8.9% 3.8% 20.8% 39.3% 4.7% 8.4% 24.1% 22.6% S8N13 9.7% 9.8% 15.7% 1.8% 14.7% 27.6% 4.5% 6.6% 13.4% 9.5% S9N9 17.7% 12.0% 27.4% 8.9% 23.9% 30.3% 24.8% 7.4% 25.6% 17.6% S9N11 17.7% 8.2% 21.8% 4.4% 22.5% 27.7% 7.8% 13.9% 24.6% 21.3% S9N12 19.6% 6.5% 23.7% 4.1% 24.1% 35.5% 6.8% 6.8% 14.4% 12.9% S11N7 13.9% 5.8% 9.8% 2.3% 11.4% 17.0% 5.8% 6.7% 8.3% 14.7% S11N8 9.9% 9.3% 12.9% 2.9% 9.6% 18.4% 5.7% 6.1% 11.9% 16.7% S11N9 6.0% 6.8% 11.5% 0.5% 10.6% 20.3% 0.9% 4.3% 11.8% 16.2% S7S11 5.9% 13.6% 4.8% 7.9% 16.8% 14.5% 5.2% 5.6% 12.9% 19.7% S7S12 4.1% 9.2% 4.9% 4.7% 4.9% 5.8% 3.5% 5.4% 2.9% 10.6% S8S11 4.9% 8.6% 3.3% 4.5% 5.9% 3.9% 5.7% 7.6% 6.8% 21.8% S8S12 5.4% 8.7% 5.5% 5.4% 12.4% 6.3% 4.6% 17.2% 1.7% 11.7% S9S12 7.9% 8.5% 2.4% 0.0% 10.8% 10.9% 2.7% 15.8% 19.6% 8.9% S9S14 1.4% 7.3% 2.5% 3.6% 7.32% 9.6% 6.2% 10.8% 14.8% 7.5% S9S15 1.3% 5.9% 1.4% 5.8% 4.4% 23.7% 2.8% 11.1% 12.6% 28.7% S9S16 0.0% 0.7% 0.0% 6.2% 11.7% 27.8% 4.2% 11.6% 6.9% 28.6% Lipofectamine2000 21.5%

Example 8: Transfection of MCF7 Cell Line with Amino Lipid Compounds as DNA Vectors

[0271] Cell line: MCF7 cells (ATCC HTB-22)

[0272] Medium DMEM supplemented with 131 fetal bovine serum

[0273] Screening: cell transfection on 96-well plates

[0274] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). Lipofectamine2000 was used as the positive control, according to the manufacturer's instructions.

[0275] Method: the experimental method was basically the same with Example 4.

[0276] Results: the absolute DNA transfection efficiency in MCF7 cells for 102 compounds is shown in Table 12.

TABLE-US-00018 TABLE 12 Absolute DNA transfection efficiency in MCF7 cells for 102 compounds. D3 D5 D6 D8 D9 D10 S8N11 3.6% 16.7% 18.0% 4.4% 45.4% 45.3% S8N12 13.7% 29.2% 25.5% 2.1% 32.0% 40.6% S8N13 19.9% 24.5% 32.2% 0.9% 25.8% 41.7% S9N9 8.6% 21.2% 11.0% 7.8% 42.3% 38.9% S9N11 26.6% 17.8% 32.6% 13.1% 27.3% 36.6% S9N12 27.5% 13.7% 21.8% 6.2% 20.0% 31.7% S11N7 4.4% 4.7% 16.2% 1.7% 5.8% 10.1% S11N8 17.7% 20.1% 9.3% 0.1% 20.9% 25.6% S11N9 13.6% 23.1% 25.1% 0.9% 33.5% 48.7% S7S11 6.4% 23.3% 38.1% 12.9% 44.5% 33.8% S7S12 3.0% 27.1% 52.1% 11.5% 14.6% 44.7% S8S11 2.7% 48.3% 56.8% 12.3% 59.8% 37.2% S8S12 1.9% 26.3% 34.4% 37.7% 13.1% 37.7% S9S12 3.0% 32.0% 34.2% 7.7% 33.8% 46.0% S9S14 1.3% 17.9% 44.4% 6.4% 38.2% 50.5% S9S15 1.4% 23.0% 48.4% 3.0% 22.5% 58.8% S9S16 14.1% 26.6% 39.7% 6.2% 23.0% 36.9% Lipofectamine2000 11.7%

Example 9: Transfection of MCF7 Cell Line with Amino Lipid Compounds as mRNA Vectors

[0277] Cell line: MCF7 cells (ATCC HTB-22)

[0278] Medium: DMEM supplemented with 10 fetal bovine serum (Invitrogen)

[0279] Screening: cell transfection on 96-well plates

[0280] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). Lipofectamine2000 (Invitrogen) was used as the positive control.

[0281] Method: the experimental method was basically the same with Example 4, and the mass of EGFP mRNA (TriLink) for transfection was 50 ng per well.

[0282] Results: the absolute mRNA transfection efficiency in MCF7 cells for 102 compounds is shown in Table 13.

TABLE-US-00019 TABLE 13 Absolute mRNA transfection efficiency in MCF7 cells for 102 compounds. D3 D5 D6 D8 D9 D10 S8N11 8.0% 9.1% 6.7% 0.1% 6.6% 4.4% S8N12 20.7% 19.7% 22.5% 0.3% 16.4% 23.1% S8N13 18.1% 9.2% 33.4% 0.4% 13.3% 23.0% S9N9 12.1% 8.3% 30.7% 2.6% 21.0% 29.6% S9N11 7.9% 18.0% 37.2% 2.7% 11.8% 20.2% S9N12 15.9% 16.6% 22.4% 0.7% 16.4% 11.2% S11N7 5.8% 3.4% 4.2% 3.2% 5.1% 9.0% S11N8 8.6% 21.2% 11.0% 7.8% 42.3% 38.9% S11N9 26.6% 17.8% 32.6% 13.1% 27.3% 36.6% S7S11 6.7% 16.5% 26.1% 1.5% 3.6% 22.2% S7S12 9.4% 33.6% 19.1% 24.0% 21.2% 47.5% S8S11 20.4% 30.6% 46.3% 7.0% 34.9% 40.4% S8S12 6.7% 32.6% 50.0% 14.0% 5.3% 50.2% S9S12 6.5% 27.3% 50.4% 12.6% 5.1% 40.9% S9S14 4.4% 2.1% 12.2% 14.8% 19.1% 50.3% S9S15 1.1% 27.0% 47.3% 13.5% 27.6% 49.4% S9S16 3.0% 32.0% 34.2% 7.7% 33.8% 46.0% Lipofectamine2000 17.5%

Example 10: Screening of Amino Lipid Compounds as DNA Vectors in Cell Lines that are Difficult to be Transfected (Embryonic Stem Cells)

[0283] Cell line: embryonic stem cells (hESC2, cultured according to reported methods: Stem Cells, 2005, 23, 544-549)

[0284] Medium: mTeSR1 (STEMCELL)

[0285] Mode of screening: cell transfection on 96-well plates

[0286] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells. Lipofectamine Stem was used as the positive control.

[0287] Method: an 8-channel pipette was used for sample addition. The contents shown were for a single well of a 96-well flat plate.

[0288] 1. Stem cells were cultured to 3-5×10.sup.4 cells per well in a 96-well plate treated with matrigel.

[0289] 2. The compound (0.01 mmol) prepared in Example 1 was dissolved in 1 mL of anhydrous ethanol. After ultrasonically dissolved, 10 μL of the resultant amino lipid solution in ethanol was taken and mixed with 5 μL of DOPE solution in ethanol (0.01 in). The obtained mixture was then added with 35 μL of 0.2 M sodium acetate buffer (pH 5.6), and vortexed at a constant rotating speed for 30 s. Then, 4 μL was taken from the obtained product and added to 46 μL of 0.02 M sodium acetate buffer (pH 5.6), and vortexed at a constant rotating speed for 30 s to form a liposome solution. 5 μL of this liposome solution was mixed with 75 ng of plasmid DNA (pSin-EGFP-IRES-Puro) dissolved in 5 μL of 0.02 M sodium acetate buffer, and allowed to stay at room temperature for 30 min to form a lipid/DNA transfection complex.

[0290] 3. 10 μL of the lipid/DNA transfection complex was incubated at room temperature for 30 min, followed by addition of 90 μL mTeSR1 medium was added and mixing with a pipette. 100 μL of the mixture was added to separate wells of a 96-well culture plate and placed in an incubator containing 5% CO.sub.2 at 37° C.

[0291] 4. 48 hours after transfection, the cells were digested with 0.05% Trypsin-EDTA. The cells were resuspended in a PBS buffer and filtered. The cell suspension was placed in a flow cytometer and the number of GFP-expressing cells in no less than 2000 cells was measured so as to obtain the absolute efficiency of cell transfection. The relative efficiency of cell transfection was obtained by comparing the cell transfection efficiency with the positive control Lipofectamine Stem.

[0292] Results: the absolute DNA transfection efficiency in embryonic stem cells for 60 compounds is shown in Table 14.

TABLE-US-00020 TABLE 14 Absolute DNA transfection efficiency in embryonic stem cells for 60 compounds. D3 D5 D6 DS D9 D10 S8N11 0.2% 1.1% 0.2% 0.7% 0.5% 0.7% S9N11 0.4% 3.0% 1.4% 0.6% 6.6% 2.2% S9N12 2.3% 2.5% 1.9% 1.1% 2.7% 5.3% S11N8 4.3% 4.0% 1.7% 0.0% 3.6% 12.6% S11N9 3.7% 0.5% 1.0% 0.8% 1.4% 0.5% S8S11 0.7% 2.4% 1.6% 1.0% 1.0% 0.7% S8S12 1.5% 1.7% 3.3% 5.9% 2.9% 2.6% S9S12 5.3% 4.6% 10.5% 11.1% 7.6% 14.0% S9S14 1.6% 0.7% 2.0% 0.7% 2.5% 0.7% S9S15 1.8% 6.2% 3.7% 1.9% 21.6% 16.8% Lipofectamine Stem 7.8%

Example 11: Screening of Amino Lipid Compounds as mRNA Vectors in Cell Lines that are Difficult to be Transfected (Embryonic Stem Cells)

[0293] Cell line: embryonic stem cells (hESC2, cultured according to reported methods: Stem Cells, 2005, 23, 544-549)

[0294] Medium: mTeSR1 (STEMCELL)

[0295] Mode of screening: cell transfection on 96-well plate

[0296] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells. Lipofectamine Stem was used as the positive control.

[0297] Method: the experimental method was basically the same with Example 10, and the mass of EGFP mRNA for transfection was 50 ng per well.

[0298] Results: the absolute mRNA transfection efficiency in embryonic stem cells for 60 compounds is shown in Table 15.

TABLE-US-00021 TABLE 15 Absolute mRNA transfection efficiency in embryonic stem cells for 60 compounds. D3 D5 D6 D8 D9 D10 S8N11 2.4% 1.6% 1.9% 1.0% 1.0% 0.7% S9N11 1.7% 3.3% 5.8% 5.9% 2.9% 2.6% S9N12 4.6% 10.5% 6.1% 11.1% 7.6% 14.0% S11N8 12.8% 6.9% 2.0% 1.3% 34.8% 35.4% S11N9 22.0% 24.9% 0.7% 3.2% 33.5% 39.3% S8S11 21.4% 21.1% 10.3% 1.6% 18.1% 37.4% S8S12 17.9% 24.9% 7.1% 0.7% 16.3% 24.6% S9S12 21.4% 27.3% 9.3% 1.7% 20.6% 25.4% S9S14 19.7% 22.5% 1.7% 0.3% 16.4% 23.1% S9S15 9.2% 33.4% 2.5% 0.4% 13.3% 23.0% Lipofectamine Stem 12.8%

Example 12: Screening of Amino Lipid Compounds as mRNA Vectors in Cell Lines that are Difficult to be Transfected (Cardiomyocytes)

[0299] Cell line: cardiomyocytes (obtained from induced differentiation of hESC according to reported methods: J. Mol. Cell. Cardiol. 2011, 51, 288-298)

[0300] Medium: DMEM supplemented with 10% fetal bovine serum (Invitrogen)

[0301] Mode of screening: cell transfection on 96-well plates

[0302] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). Lipofectamine Stem (Invitrogen) was used as the positive control, according to the manufacturer's instructions.

[0303] Method: the experimental method was basically the same with Example 4.

[0304] Results: the absolute DNA transfection efficiency in cardiomyocytes for 60 compounds is shown in Table 16.

TABLE-US-00022 TABLE 16 Absolute DNA transfection efficiency in cardiomyocytes for 60 compounds. D3 D5 D6 D8 D9 D10 S8N11 0.5% 3.0% 1.4% 2.1% 0.6% 6.6% S9N11 0.4% 2.5% 1.9% 0.8% 1.1% 2.7% S9N12 1.1% 4.0% 1.7% 1.5% 0.0% 3.6% S11N8 0.2% 9.1% 6.7% 1.2% 0.1% 6.6% S11N9 0.3% 19.7% 22.5% 1.7% 0.3% 16.4% S8S11 1.9% 0.5% 1.0% 2.2% 0.8% 1.4% S8S12 0.3% 2.4% 1.6% 1.9% 1.0% 1.0% S9S12 2.7% 1.7% 3.3% 5.8% 5.9% 2.9% S9S14 0.5% 4.6% 10.5% 6.1% 11.1% 7.6% S9S15 0.3% 12.8% 6.9% 2.0% 1.3% 24.8% Lipofectamine Stem 11.2%

Example 13: Screening of Amino Lipid Compounds as mRNA Vectors in Cell Lines that are Difficult to be Transfected (Cardiomyocytes)

[0305] Cell line: cardiomyocytes (obtained from induced differentiation of hESC according to reported methods: J Mol. Cell. Cardiol. 2011, 51, 288-298)

[0306] Medium: DMEM supplemented with 10% fetal bovine serum (Invitrogen)

[0307] Mode of screening: cell transfection on 96-well plates

[0308] Detection (readout): percentage of the number of GFP fluorescent cells relative to the total number of cells (the total number of cells was determined using nucleus dye Hoechst). Lipofectamine Stem (Invitrogen) was used as the positive control, according to the manufacturer's instructions.

[0309] Method: the experimental method was basically the same with Example 4, and the mass of EGFP mRNA for transfection was 50 ng per well.

[0310] Results: the absolute mRNA transfection efficiency in cardiomyocytes for 60 compounds is shown in Table 17.

TABLE-US-00023 TABLE 17 Absolute mRNA transfection efficiency in cardiomyocytes for 60 compounds. D3 D5 D6 D8 D9 D10 S8N11 6.2% 3.7% 5.3% 1.9% 31.6% 16.8% S9N11 16.7% 18.0% 5.0% 4.4% 45.4% 45.3% S9N12 29.2% 25.5% 5.3% 2.1% 32.0% 40.6% S11N8 24.5% 32.2% 7.9% 0.9% 25.8% 41.7% S11N9 8.3% 30.7% 8.7% 2.6% 21.0% 29.6% S8S11 21.0% 2.7% 18.4% 0.7% 25.5% 20.8% S8S12 36.7% 2.5% 44.9% 0.7% 14.0% 25.6% S9S12 65.7% 1.2% 9.5% 0.9% 69.3% 3.8% S9S14 72.4% 0.6% 8.5% 1.0% 12.4% 34.4% S9S15 6.6% 1.9% 12.9% 0.6% 7.1% 4.3% Lipofectamine Stem 17.3%

Abbreviation List

[0311] DMEM Basic high-glucose medium

[0312] DNA deoxyribonucleic acid

[0313] DOPE dioleoylphosphatidylethanolamine

[0314] DSPC Distearoyl Phosphatidylcholine

[0315] PEG2000-DMG 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000

[0316] GFP green fluorescent protein

[0317] EGFP enhanced GFP

[0318] KD kilodalton

[0319] RNA ribonucleic acid

[0320] THF tetrahydrofuran

[0321] DIPEA N,N-diisopropylethylamine

[0322] PBS phosphate buffered solution

[0323] Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All references cited in this application (including all patents, patent applications, journal articles, books and any other publications) are incorporated in their entirety herein by reference.